

December 2016**A. GENERAL INFORMATION**

Name: Mithat Gönen, Ph.D.

Office Address: Memorial Sloan-Kettering Cancer Center
1275 York Avenue Box 44
New York, NY 10021
Telephone: (646) 735-8111
Fax: (646) 735-0010
E-mail: gonenm@mskcc.org

B. EDUCATIONAL BACKGROUND

Degree	Institution	Dates Attended	Year
B.S Electrical Engineering	Middle East Technical University Ankara, Turkey	09/86-06/91	1991
M.S Industrial Engineering	Stanford University Stanford, California	09/92-08/93	1993
M.S Statistics	Texas Tech University Lubbock, Texas	09/93-08/96	1996
Ph.D. Statistics	Texas Tech University Lubbock, Texas	09/93-12/96	1996

C. PROFESSIONAL POSITIONS AND EMPLOYMENT**Academic Appointments:**

Title	Institution name and location	Dates held
Biostatistician	Applied Logic Associates, Houston, TX	12/96-08/98
Senior Statistical Scientist	Applied Logic Associates, Houston, TX	08/98-08/99
Assistant Member	Memorial Sloan-Kettering Cancer Center New York, NY	08/99-03/05
Associate Member, MH	Memorial Sloan-Kettering Cancer Center New York, NY	03/05-01/12
Member, MH	Memorial Sloan-Kettering Cancer Center New York, NY	01/12-Present

Hospital Positions

Title	Institution name and location	Dates held
Assistant Attending Biostatistician	Dept. of Epidemiology and Biostatistics Memorial Hospital for Cancer and Allied Diseases, New York, NY	08/99-03/05
Associate Attending Biostatistician	Dept. of Epidemiology and Biostatistics Memorial Hospital for Cancer and Allied Diseases, New York, NY	03/05-01/12
Attending Biostatistician	Dept. of Epidemiology and Biostatistics Memorial Hospital for Cancer and Allied Diseases, New York, NY	01/12- Present
Chief Attending	Dept. of Epidemiology and Biostatistics Memorial Hospital for Cancer and Allied Diseases, New York, NY	02/15- Present

CURRICULUM VITAE**Mithat Gönen, Ph.D.****Other Employment:**

Title	Institution name and location	Dates held
Teaching/Research Assistant	Middle East Technical University Ankara, Turkey	09/90-08/91
Teaching Assistant	Texas Tech University, Lubbock, Texas	09/91-08/92
Teaching Assistant	Texas Tech University, Lubbock, Texas	09/94-08/95

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

Not applicable

E. PROFESSIONAL MEMBERSHIPS

Member/Officer	Name of Organization	Dates held
Member	American Statistical Association	1996-present
Member	International Biometric Society	1996-present
Member	Society for Clinical Trials	2009-present
Member	American Society of Clinical Oncology	2011-present

F. HONORS AND AWARDS

Fellow of the American Statistical Association, 2012

G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation Memorial Hospital for Cancer and Allied Diseases, NY

H. EMPLOYMENT STATUS

Memorial Sloan Kettering Cancer Center Full-time

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT**1. Teaching:**

- Lecturer of Biostatistics, Weill Medical School, Cornell University, 1999-2001
- Lecturer of Biostatistics for Clinical Fellows, Departments of Surgery, Radiology and Pathology, 2005-present

2. Clinical Care

N/A

3. Administrative

- Member, Junior Faculty Council, 2004-2005
- Member, Research Council, 2005-2014
- Member, Data Integrity Investigation Committee, 2008-2009.
- Director and Faculty, Clinical Trials Workshop, 2008-2010.

4. Research:

- Developing novel Bayesian methods for design and analysis of clinical data (1999-present).
- Collaboration with gastrointestinal oncologists to design clinical trials on novel therapies to treat cancers of colon, rectum, stomach, esophagus and liver (1999-2005).
- Collaboration with Nuclear Medicine Physicians to design and analyze prospective and retrospective studies on the use of PET in various cancers (1999-present).
- Collaboration with gastrointestinal surgeons to design and analyze prospective and retrospective studies on patient selection, outcome prediction and outcome improvement for surgical treatment (2001-present).
- Using ROC curves in studies of cancer diagnosis and prognosis (2003-present).
- Developing novel statistical methods to assess and validate prognostic models and cancer staging systems (2004-present)
- Genomic predictors of outcome in Acute Myeloid Leukemia (2010-present).
- Design and analysis of early-phase molecular imaging studies (2011-present)
- Phase II clinical trial design with historical controls (2012-present)

CURRICULUM VITAE**Mithat Gönen, Ph.D.**

Activity	Current Percent Effort (%)	Does the activity involve WMC or researchers?(Y/N)	Does the activity involve MSK trainees or researchers? (Y/N)
Teaching/Mentoring	5%	N	Y
Clinical Care	0%	N/A	N/A
Administration	0%	N/A	N/A
Research	95%	Y	Y
TOTAL:	100%		

J. CURRENT RESEARCH SUPPORT

- Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT (PI: Nehmeh), NCI U01 CA157442, 5/1/2012 - 4/30/2016, 8% effort as a Co-Investigator.
- Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Radiotherapeutic Platforms for Nanomedicine (PI: Bradbury), NCI R01 CA161280, 3/12/2012 - 6/30/2017, 5% effort as a Co-Investigator.
- First Human Trial of Src/Abl-Targeted Cancer Imaging with F-18 SKI249380 PET (PI: Dunphy), NCI R21 CA167803, 9/19/2012 - 8/31/2016, 6% effort as a Co-Investigator.
- Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET (PI: Lewis), NCI R01 CA176671, 4/1/2013 - 3/31/2018, 7% effort as a Co-Investigator.
- Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model (PI: Schwartz), NCI (U01 CA140207, subcontract from Columbia University, 9/1/2011-8/31/2016, 12% effort as a Co-Investigator.
- Predictive MRI metrics for tumor aggressiveness in micropapillary thyroid cancer (PI: Dave), NCI R21 CA176660, 3/1/2014-2/28/2017, 2% effort as a Co-Investigator.
- ECOG ACRIN Integrated Leukemia Translational Research Center (PI: Paietta), NCI U01 CA180827, 3/1/2014-2/28/2019, 7.5% effort as a Co-Investigator.
- Cancer Center Support Grant (Biostatistics Core) (PI: Thompson), P30 CA008748, 1/1/2014-12/31/2018, 5% effort as a Co-Investigator.
- (PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer (PI: Iacobuzio-Donahue), R01 CA179991, 9/9/2014-6/30/2017, 2% effort as a Co-Investigator.
- SPORC in Thyroid Cancer - Core B: Biostatistics Core (PI: Fagin/Seshan), P50 CA172012, 9/19/2014 -8/31/2019, 12% effort as a Co-Investigator.
- Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas (PI: Allen), R01 CA182076, 9/1/2014-8/31/2019 , 8% effort as a Co-Investigator.
- Development of Nuclear Auger Emitters for Targeted Radiotherapy, (PI: Reiner/Weber), NCI R21-CA191679, 9/1/2015-8/31/2017, 5% effort as a Co-Investigator
- MSKCC-Cornell Center for Translation of Cancer Nanomedicines (PI: Bradbury), U54-

CURRICULUM VITAE

Mithat Gönen, Ph.D.

CA199081, 8/27/2015-7/31/2020, 8% effort as a Co-Investigator

- MSKCC Center for Molecular Imaging in Cancer (Special Resource C (SR-C) - Quantitative Imaging: Biostatistics and Medical Physics)(PI: Larson/Humm), P50-CA086438, 9/16/2011-6/30/2016, 5% effort as a Co-Investigator
- Reproducibility of Hyperpolarized Pyruvate Metabolic Imaging in Prostate Cancer (PI: Hricak/Rehimi-Keshari), R01-CA195476, 12/1/2015-11/30/2018, 4% effort as a Co-Investigator

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

- AACR Methods in Cancer Biostatistics Workshop, Lake Tahoe, CA
 - Faculty, 2015
- AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO
 - Faculty, 2007-2013
 - Program Committee Member, 2009-2010
 - Co-Director, 2011-2013
- ASCO Cancer Research Committee, 2012-2016
- Society for Clinical Trials
 - Chair, Program Committee, 2012 Annual Meeting
 - Member, Board of Directors, 2013-2016
 - Secretary, 2016-2018
- American Statistical Association
 - Treasurer, Houston Area Chapter, 1997-1999
 - New York City Chapter
 - Executive Committee Member, 2001-2003.
 - Vice President, 2003-2008.
 - Committee on International Relations in Statistics
 - Member, 2006-2011
 - President, 2010-2011
 - Advisory Committee on Continuing Education,
 - Member, 2011-2016
 - Chair-Elect, 2014-2015
 - Chair, 2015-2016
- International Biometric Society
 - Member, ENAR Advisory Board, 2012-2014
 - Program Chair, ENAR Spring Meeting, 2015
- Editorial Boards
 - Member, Editorial Board, *Gastrointestinal Cancer Research*, 2007-2012.
 - Associate Editor, *Clinical Trials: Journal of the Society for Clinical Trials*, 2008-2013.
 - Deputy Editor, *Clinical Trials: Journal of the Society for Clinical Trials*, 2013-present.

CURRICULUM VITAE

Mithat Gönen, Ph.D.

- Associate Editor, *Statistics in Biopharmaceutical Research*, 2014-present.
- Statistical Editor, *Journal of the National Cancer Institute*, 2014-2015.
- National Institutes of Health
 - Member, NIH Review Panel “Genetic and Molecular Mechanisms of CAD Susceptibility and Progression” 2005
 - Member, NIH Review Panel “Specialized Centers For Cell-Based Therapy (SCCT) For Heart, Lung, and Blood Diseases and Data and Coordinating Center (DCC)” 2005
 - Member, Common Data Elements Committee For Phase II Clinical Trials, NCI, Cancer Therapy Evaluation Program. 2005-2006
 - Member, NCI Study Section, Subcommittee J on Population and Patient-Based Training. 2006-2008.
 - Reviewer, Deutsche Forschungsgemeinschaft (German Research Foundation) Life Sciences, 2007-2008.
 - Reviewer, National Institute for Health Research UK, 2008.
 - Member, NIH Special Emphasis Panel “NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03)”, 2009.
- Data Safety and Monitoring Boards
 - Member, Data Safety and Monitoring Board, “Antiviral and Antifibrotic Liver Therapy of HCV⁺ Drinkers.” NIH-supported multi-center randomized trial. 2004-2008
 - Member, Data Safety and Monitoring Board, “Home-Based Blood Pressure Interventions for African Americans.” NIH-supported multi-center randomized trial. 2005-2009
 - Member, Data Safety and Monitoring Board, “A Randomized, Placebo-Controlled, Phase 1/2 Study Of Arq197 In Combination With Irinotecan And Cetuximab In Subjects With Colorectal Cancer With Wild-Type Kras Who Have Received Front-Line Systemic Therapy” Daiichi-Sankyo Protocol ARQ 197 A-U-252, 2010-2013.
 - Member, Data Safety and Monitoring Board, “A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients with Stage IV (including Pleural Effusion) Non Squamous Non Small Cell Lung Cancer (NSCLC) who have Failed Two Lines of Anti-Cancer Therapy” GHNSCLC-2-001.

INVITED SEMINARS

1. *Bayesian analysis of variance components with Dirichlet priors.* Conference of Texas Statisticians, Houston, Texas, April 1997.
2. *Bayesian analysis of intraclass correlations in the mixed linear model.* Universite Catholique de Louvaine, Institute of Statistiques, Louvain-la-neuve, Belgium, March 1998.
3. *Bayesian methods in signal processing.* Rice University, Digital Signal Processing Research Group, Houston, Texas, October 1998.

CURRICULUM VITAE

Mithat Gönen, Ph.D.

4. *Bayes and frequentist methods for multiple inferences in drug experiments.* 1999
International Biometric Society (ENAR) Regional Conference, Atlanta, GA, March 1999.
5. *Bayesian multiple testing with correlated priors.* Southern Research Council on Statistics (SRCOS) Summer Conference, Mountain View, AR, June 1999.
6. *Bayesian multiple testing of multiple endpoints in clinical trials.* M.D. Anderson Cancer Center, Department of Biostatistics, Houston, TX, March 2000.
7. *A Bayesian look at the two-sample multivariate problem: connections with multiple testing.* New York State Psychiatric Institute, New York, NY, November 2002.
8. *Analysis of clustered binary pairs.* Texas Tech University, Department of Mathematics and Statistics, Lubbock, TX, April 2003.
9. *Testing marginal homogeneity with clustered binary data.* Penn State Medical School, Hershey, PA, September 2003. *Clinical trials and molecular biology.* New Jersey Cancer Institute, New Brunswick, NJ. March 2005.
10. *Receiver operating characteristic curves.* SAS Users Group International 31, San Francisco, CA. March 2006.
11. *Receiver operating characteristic curves.* Northeast SAS Users Group, Philadelphia, PA September 2006.
12. *Estimation Of Concordance Probability With Censored Data And Its Applications In Cancer Staging.* Columbia University Department of Biostatistics, October 2006.
13. *Estimation of Concordance with Censored Data.* Johns Hopkins University, Bloomberg School of Public Health, November 2007.
14. *Concordance Probability in Presence of Censoring with Applications to Cancer Staging and Biomarkers.* Stanford University, Department of Biostatistics, February 2008.
15. *ROC Curves for the Uninitiated.* (Tutorial) International Biometric Society (ENAR) Spring Conference, Washington DC, March 2008.
16. *Evaluation of Prognostic Models using Area Between Curves (ABC).* Joint Statistical Meetings, Denver, CO, August 2008.
17. *Statistical Aspects of Gene Signatures and Molecular Targets.* International Society of Gastrointestinal Oncology, Arlington, VA. September 2008.

18. *An extension of the c-index for Cox models*. Cleveland Clinic Foundation, Department of Quantitative Sciences. October 2008.
19. *Evaluation and Validation of Cox Models Using Concordance Probability*. University of Wisconsin, Department of Biostatistics and Bioinformatics, February 2009.
20. *ROC Curves without Tears*. (Short Course) International Biometric Society (EMR) Conference, Istanbul, Turkey, May 2009.
21. *Statistical Issues in Solid Tumor Response Assessment*, Roundtable Discussion Leader, FDA/Industry Statistics Workshop, Washington DC, September 2009.
22. *Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer*. Bayesian Biostatistics 2010, Houston, TX, January 2010.
23. *Estimation of Concordance Probability with Censored Data*. Duke University, Department of Biostatistics, February 2010.
24. *Simultaneous Use of Historical and Randomized Controls in Phase II Trials*. Society of Clinical Trials Meeting, Baltimore, MD, May 2010.
25. *Composite Regression for Predictive Values*. Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, May 2010.
26. *Nonparametric Estimation of Concordance Probability with Censored Data*. Joint Statistical Meetings, Vancouver, BC, August 2010.
27. *Nonparametric and Semiparametric Estimation of Concordance Probability with Censored Data*. University of Pennsylvania, Department of Biostatistics, October 2010.
28. *Estimation of Molecular and Genetic Diversity*. Bilkent University, Ankara, Turkey, September 2011.
29. *Comparing ROC Curves from Nested Models*. Conference on Risk Assessment and Evaluation of Predictions, Silver Spring, MD, October 2011.
30. *ROC Curves without Tears*. Hospital for Special Surgery, New York, NY, October 2011.

31. *Combining Randomized and Historical Controls for Phase II Trials*, The Ninth Annual Conference on Frontiers in Applied and Computational Mathematics (FACM '12), New Jersey Institute of Technology, Newark, NJ, May 2012.
32. *Bayesian Phase II Designs Using Historical and Concurrent Controls*, Novartis Statistical Methodology Group, Basel, Switzerland, August 2012.
33. *Comparing Reclassification Indices Derived from Regression Models*. Inserm Atelier 223, Bordeaux, France, May 2013.
34. *Using ROC Curves and Reclassification Measures to Evaluate the Incremental Utility of Novel Markers*, Inserm Unit 1153 Invited Lecture, Paris, France, April 2014.
35. *Historical Controls and Bayesian Analysis in Phase II trials*. Society of Clinical Trials Meeting, Baltimore, MD, May 2014.
36. *Genomic Profiling and Prognostic Refinement in Acute Myeloid Leukemia Using the Boomerang Method*, Icahn School of Medicine at Mt Sinai, Department of Preventive Medicine Ground Rounds, September 2014.
37. *Model-Based Concordance for External Validation of Predictive Models with Censored Data*. International Biometric Society Eastern Mediterranean Region Conference, May 2015.
38. *External Validation of Predictive Models with Censored Data*. International Conference on Information Complexity and Statistics, May 2016.

L. BIBLIOGRAPHY

Peer-Reviewed Articles

1. Westfall PH and **Gönen M**. Asymptotic properties of ANOVA Bayes factors. *Communications in Statistics - Theory and Methods*. 1996. 25(12): p. 3101-3123.
2. **Gönen M**. A Bayesian analysis of the intraclass correlations in the mixed linear model. *Communications in Statistics - Theory and Methods*. 2000. 29(7): p. 1451-1464.
3. **Gönen M**, Puri ML, Ruymgaart FH, and Van Zuijlen MCA. The limiting density of unit root test statistics: A unifying technique. *Journal of Time Series Analysis*. 2000. 21(3): p. 249-260.
4. Motwani M, Jung C, Sirotiak FM, She Y, Shah MA, **Gönen M**, and Schwartz GK. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. *Clinical Cancer Research*. 2001. 7(12): p. 4209-4219.
5. Kemeny NE, **Gönen M**, Sullivan D, Schwartz L, Benedetti F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J, Tong W, and Paty P. Phase I study of hepatic arterial infusion of

- floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. *Journal of Clinical Oncology*. 2001. 19(10): p. 2687-2695.
6. Yeung HWD, Cody Iii HS, Turlakow A, Riedel ER, Fey J, **Gönen M**, Nuñez R, Yeh SD, and Larson SM. Lymphosintigraphy and sentinel node localization in breast cancer patients: A comparison between 1-day and 2-day protocols. *Journal of Nuclear Medicine*. 2001. 42(3): p. 420-423.
 7. Abraham MT, **Gönen M**, and Kraus DH. Complications of type I thyroplasty and arytenoid adduction. *Laryngoscope*. 2001. 111(8): p. 1322-1329.
 8. Turlakow A, Larson SM, Coakley F, Akhurst T, **Gönen M**, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, and Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: Comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. *Quarterly Journal of Nuclear Medicine*. 2001. 45(3): p. 235-244.
 9. **Gönen M**, Panageas KS, and Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. *Radiology*. 2001. 221(3): p. 763-767.
 10. Ramos CD, Erdi YE, **Gönen M**, Riedel E, Yeung HWD, Macapinlac HA, Chisin R, and Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. *European Journal of Nuclear Medicine*. 2001. 28(2): p. 155-164.
 11. Jarnagin WR, Fong Y, DeMatteo RP, **Gönen M**, Burke EC, Bodniewicz J, Youssef M, Klimstra D, and Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Annals of Surgery*. 2001. 234(4): p. 507-519.
 12. Allen PJ, Stojadinovic A, Ben-Porat L, **Gönen M**, Kooby D, Blumgart L, Paty P, and Fong Y. The management of variant arterial anatomy during hepatic arterial infusion pump placement. *Annals of Surgical Oncology*. 2002. 9(9): p. 875-880.
 13. Nuñez R, Macapinlac HA, Yeung HWD, Akhurst T, Cai S, Osman I, **Gönen M**, Riedel E, Scher HI, and Larson SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. *Journal of Nuclear Medicine*. 2002. 43(1): p. 46-55.
 14. Etchebehere ECSC, Macapinlac HA, **Gönen M**, Humm J, Yeung HWD, Akhurst T, Scher HI, and Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions on 18F-FDG PET. *Quarterly Journal of Nuclear Medicine*. 2002. 46(2): p. 122-130.
 15. Ross PL, Gerigk C, **Gönen M**, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, and Kattan MW. Comparisons of nomograms and urologists' predictions in prostate cancer. *Seminars in Urologic Oncology*. 2002. 20(2): p. 82-88.
 16. Akhurst T, Downey RJ, Ginsberg MS, **Gönen M**, Bains M, Korst R, Ginsberg RJ, Rusch VW, and Larson SM. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. *Annals of Thoracic Surgery*. 2002. 73(1): p. 259-266.
 17. Panageas KS, Smith A, **Gönen M**, and Chapman PB. An optimal two-stage phase II design utilizing complete and partial response information separately. *Controlled Clinical Trials*. 2002. 23(4): p. 367-379.

18. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, **Gönen M**, and Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. *Surgery*. 2002. 132(2): p. 353-359.
19. Kemeny N, Tong W, **Gönen M**, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, and Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. *Annals of Oncology*. 2002. 13(9): p. 1490-1496.
20. Petrowsky H, **Gönen M**, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, and Fong Y. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: A Bi-institutional analysis. *Annals of Surgery*. 2002. 235(6): p. 863-871.
21. Jarnagin WR, **Gönen M**, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH, and Nagorney DM. Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade. *Annals of Surgery*. 2002. 236(4): p. 397-407.
22. Holen KD, Klimstra DS, Hummer A, **Gönen M**, Conlon K, Brennan M, and Saltz LB. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. *Journal of Clinical Oncology*. 2002. 20(24): p. 4673-4678.
23. Wong RJ, Lin DT, Schöder H, Patel SG, **Gönen M**, Wolden S, Pfister DG, Shah JP, Larson SM, and Kraus DH. Diagnostic and prognostic value of [18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *Journal of Clinical Oncology*. 2002. 20(20): p. 4199-4208.
24. Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, **Gönen M**, Haimovitz-Friedman A, and Schwartz GK. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates γ -Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells. *Clinical Cancer Research*. 2003. 9(16 I): p. 6052-6061.
25. Yeung HWD, Grewal RK, **Gönen M**, Schöder H, and Larson SM. Patterns of 18F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET. *Journal of Nuclear Medicine*. 2003. 44(11): p. 1789-1796.
26. Hann LE, Kim CM, **Gönen M**, Barakat R, Choi PH, and Bach AM. Sonohysterography Compared With Endometrial Biopsy for Evaluation of the Endometrium in Tamoxifen-Treated Women. *Journal of Ultrasound in Medicine*. 2003. 22(11): p. 1173-1179.
27. Pandit N, **Gönen M**, Krug L, and Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. *European Journal of Nuclear Medicine and Molecular Imaging*. 2003. 30(1): p. 78-84.
28. Kooby DA, Fong Y, Suriawinata A, **Gönen M**, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, and Jarnagin WR. Impact of steatosis on perioperative outcome following hepatic resection. *Journal of Gastrointestinal Surgery*. 2003. 7(8): p. 1034-1044.
29. Flores RM, Akhurst T, **Gönen M**, Larson SM, Rusch VW, Sugarbaker DJ, Miller D, Smythe WR, and Vallieres E. Positron emission tomography defines metastatic disease but not

- locoregional disease in patients with malignant pleural mesothelioma. *Journal of Thoracic and Cardiovascular Surgery*. 2003. 126(1): p. 11-16.
30. **Gönen M**. Planning for subgroup analysis: A case study of treatment-marker interaction in metastatic colorectal cancer. *Controlled Clinical Trials*. 2003. 24(4): p. 355-363.
 31. Shoup M, **Gönen M**, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong Y, Aranha GV, Tsiotos GG, Sauvanet A, Deshpande R, and Young-Fadok TM. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *Journal of Gastrointestinal Surgery*. 2003. 7(3): p. 325-330.
 32. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, **Gönen M**, and Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. *Journal of Urology*. 2003. 170(4 I): p. 1184-1188.
 33. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, **Gönen M**, Reuter V, and Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. *Journal of Urology*. 2003. 170(6 I): p. 2292-2295.
 34. Kooby DA, Stockman J, Ben-Porat L, **Gönen M**, Jarnagin WR, Dematteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y, Bolton JS, Choti MA, Clary B, Baisden CE, and Fong Y. Influence of Transfusions on Perioperative and Long-Term Outcome in Patients Following Hepatic Resection for Colorectal Metastases. *Annals of Surgery*. 2003. 237(6): p. 860-870.
 35. **Gönen M**, Westfall PH, and Johnson WO. Bayesian multiple testing for two-sample multivariate endpoints. *Biometrics*. 2003. 59(1): p. 76-82.
 36. Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, **Gönen M**, Wilson K, and Minsky BD. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. *Journal of Clinical Oncology*. 2003. 21(15): p. 2926-2932.
 37. Kemeny N, Jarnagin W, **Gönen M**, Stockman J, Blumgart L, Sperber D, Hummer A, and Fong Y. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. *Journal of Clinical Oncology*. 2003. 21(17): p. 3303-3309.
 38. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, **Gönen M**, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, and Rusch V. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. *Journal of Clinical Oncology*. 2003. 21(3): p. 428-432.
 39. **Gönen M**, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, and Kemeny N. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. *Journal of Clinical Oncology*. 2003. 21(3): p. 406-412.
 40. Weitz J, D'Angelica M, **Gönen M**, Klimstra D, Coit DG, Brennan MF, and Karpeh MS. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. *Journal of Clinical Oncology*. 2003. 21(24): p. 4597-4603.

41. D'Angelica M, Fong Y, Weber S, **Gönen M**, DeMatteo RP, Conlon K, Blumgart LH, and Jarnagin WR. The role of staging laparoscopy in hepatobiliary malignancy: Prospective analysis of 401 cases. *Annals of Surgical Oncology*. 2003. 10(2): p. 183-189.
42. Pandit-Taskar N, Schöder H, **Gönen M**, Larson SM, and Yeung HWD. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. *American Journal of Roentgenology*. 2004. 183(4): p. 1143-1147.
43. Brenner B, Shah MA, **Gönen M**, Klimstra DS, Shia J, and Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: A retrospective study of 64 cases. *British Journal of Cancer*. 2004. 90(9): p. 1720-1726.
44. Schöder H, Erdi YE, Chao K, **Gönen M**, Larson SM, and Yeung HWD. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. *Journal of Nuclear Medicine*. 2004. 45(4): p. 559-566.
45. Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, **Gönen M**, Kattan MW, Onyebuchi CN, and Scardino PT. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. *Cancer*. 2004. 100(12): p. 2655-2663.
46. Carlo WF, Hummer AJ, Schwartz L, Sullivan D, **Gönen M**, Jarnagin W, Fong Y, and Kemeny N. Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. *Journal of Surgical Oncology*. 2004. 87(2): p. 85-90.
47. **Gönen M**. Sample size and power for McNemar's test with clustered data. *Statistics in Medicine*. 2004. 23(14): p. 2283-2294.
48. Weitz J, D'Angelica M, Jarnagin W, **Gönen M**, Fong Y, Blumgart L, and DeMatteo R. Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. *Surgery*. 2004. 135(3): p. 273-281.
49. D'Angelica M, **Gönen M**, Brennan MF, Turnbull AD, Bains M, and Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. *Annals of Surgery*. 2004. 240(5): p. 808-816.
50. Schöder H, Yeung HWD, **Gönen M**, Kraus D, and Larson SM. Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. *Radiology*. 2004. 231(1): p. 65-72.
51. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, **Gönen M**, Segal NH, Maki RG, Socci ND, DeMatteo RP, and Besmer P. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. *Clinical Cancer Research*. 2004. 10(10): p. 3282-3290.
52. Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, **Gönen M**, and Fong Y. Infection with Oncolytic Herpes Simplex Virus-1 Induces Apoptosis in Neighboring Human Cancer Cells: A Potential Target to Increase Anticancer Activity. *Clinical Cancer Research*. 2004. 10(9): p. 3225-3232.
53. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, **Gönen M**, and Kelsen DP. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. *Journal of Clinical Oncology*. 2004. 22(1): p. 45-52.

54. Downey RJ, Akhurst T, **Gönen M**, Vincent A, Bains MS, Larson S, and Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. *Journal of Clinical Oncology*. 2004. 22(16): p. 3255-3260.
55. Vural B, Chen LC, Saip P, Chen YT, Ustuner Z, **Gönen M**, Simpson AJG, Old LJ, Ozbek U, and Gure AO. Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. *Cancer*. 2005. 103(12): p. 2575-2583.
56. Liau KH, Ruo L, Shia J, Padelá A, **Gönen M**, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, and DeMatteo RP. Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. *Cancer*. 2005. 104(9): p. 1948-1955.
57. Kemeny N, Eid A, Stockman J, **Gönen M**, Schwartz L, Tetzlaff E, and Paty P. Hepatic arterial infusion of Floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. *Journal of Surgical Oncology*. 2005. 91(2): p. 97-101.
58. **Gönen M**. Planning a dose-response study with subject-specific doses. *Statistics in Medicine*. 2005. 24(17): p. 2613-2623.
59. Yeung HWD, Schöder H, Smith A, **Gönen M**, and Larson SM. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. *Molecular Imaging and Biology*. 2005. 7(3): p. 229-235.
60. **Gönen M**. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. *Contemporary Clinical Trials*. 2005. 26(2): p. 131-140.
61. Hawkins WG, DeMatteo RP, Cohen MS, Jarnagin WR, Fong Y, D'Angelica M, **Gönen M**, and Blumgart LH. Caudate hepatectomy for cancer: A single institution experience with 150 patients. *Journal of the American College of Surgeons*. 2005. 200(3): p. 345-352.
62. Bennett JJ, **Gönen M**, D'Angelica M, Jaques DP, Brennan MF, and Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? *Journal of the American College of Surgeons*. 2005. 201(4): p. 503-510.
63. Kemeny NE and **Gönen M**. Hepatic arterial infusion after liver resection [7]. *New England Journal of Medicine*. 2005. 352(7): p. 734-735.
64. **Gönen M** and Heller G. Concordance probability and discriminatory power in proportional hazards regression. *Biometrika*. 2005. 92(4): p. 965-970.
65. Yanke BV, **Gönen M**, Scardino PT, and Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. *Journal of Urology*. 2005. 173(2): p. 421-424.
66. Kraus DH, **Gönen M**, Mener D, Brown AE, Bilsky MH, and Shah JP. A standardized regimen of antibiotics prevents infectious complications in skull base surgery. *Laryngoscope*. 2005. 115(8): p. 1347-1357.
67. Spanknebel K, Coit DG, Bieligg SC, **Gönen M**, Rosai J, and Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology:

- Recommendations for standardizing pathologic analysis. *American Journal of Surgical Pathology*. 2005. 29(3): p. 305-317.
68. Howard MA, Cordeiro PG, Disa J, Samson W, **Gönen M**, Schoelle RN, and Mehrara B. Free tissue transfer in the elderly: Incidence of perioperative complications following microsurgical reconstruction of 197 septuagenarians and octogenarians. *Plastic and Reconstructive Surgery*. 2005. 116(6): p. 1659-1668.
69. Maluccio M, Covey AM, Gandhi R, **Gönen M**, Getrajdman GI, Brody LA, Fong Y, Jarnagin W, D'Angelica M, Blumgart L, Dematteo R, and Brown KT. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. *Journal of Vascular and Interventional Radiology*. 2005. 16(7): p. 955-961.
70. Fong Y, **Gönen M**, Rubin D, Radzyner M, Brennan MF, Nagorney DM, Warshaw AL, Jeekel JH, Cameron JL, Polk Jr HC, Munoz E, Roberts JP, and Lewis FR. Long-term survival is superior after resection for cancer in high-volume centers. *Annals of Surgery*. 2005. 242(4): p. 540-547.
71. Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, **Gönen M**, and Schwartz GK. Drg1 expression in 131 colorectal liver metastases: Correlation with clinical variables and patient outcomes. *Clinical Cancer Research*. 2005. 11(9): p. 3296-3302.
72. Shah MA, Kortmansky J, Motwani M, Drobnjak M, **Gönen M**, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, and Schwartz GK. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. *Clinical Cancer Research*. 2005. 11(10): p. 3836-3845.
73. Schöder H, Herrmann K, **Gönen M**, Hricak H, Eberhard S, Scardino P, Scher HI, and Larson SM. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. *Clinical Cancer Research*. 2005. 11(13): p. 4761-4769.
74. Gure AO, Chua R, Williamson B, **Gönen M**, Ferrera CA, Gnjjatic S, Ritter G, Simpson AJG, Chen YT, Old LJ, and Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. *Clinical Cancer Research*. 2005. 11(22): p. 8055-8062.
75. **Gönen M**, Johnson WO, Lu Y, and Westfall PH. The Bayesian two-sample t test. *American Statistician*. 2005. 59(3): p. 252-257.
76. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, **Gönen M**, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, and Schwartz GK. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. *Journal of Clinical Oncology*. 2005. 23(9): p. 1875-1884.
77. Kemeny N, Jarnagin W, Paty P, **Gönen M**, Schwartz L, Morse M, Leonard G, D'Angelica M, DeMatteo R, Blumgart L, and Fong Y. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. *Journal of Clinical Oncology*. 2005. 23(22): p. 4888-4896.

78. Schöder H, Noy A, **Gönen M**, Weng L, Green D, Erdi YE, Larson SM, and Yeung HWD. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. *Journal of Clinical Oncology*. 2005. 23(21): p. 4643-4651.
79. Specht MC, Kattan MW, **Gönen M**, Fey J, and Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: Clinicians versus nomogram. *Annals of Surgical Oncology*. 2005. 12(8): p. 654-659.
80. Stiles BM, Adusumilli PS, Stanziale SF, Eisenberg DP, Bhargava A, Kim TH, Chan MK, Huq R, **Gönen M**, and Fong Y. Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. *International Journal of Oncology*. 2006. 28(6): p. 1429-1439.
81. Schöder H, Carlson DL, Kraus DH, Stambuk HE, **Gönen M**, Erdi YE, Yeung HWD, Huvos AG, Shah JP, Larson SM, and Wong RJ. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. *Journal of Nuclear Medicine*. 2006. 47(5): p. 755-762.
82. Pryma DA, Schöder H, **Gönen M**, Robbins RJ, Larson SM, and Yeung HWD. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. *Journal of Nuclear Medicine*. 2006. 47(8): p. 1260-1266.
83. Santiago JFY, **Gönen M**, Yeung H, Macapinlac H, and Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*. 2006. 50(1): p. 61-67.
84. D'Angelica M, Maddineni S, Fong Y, Martin RCG, Cohen MS, Ben-Porat L, **Gönen M**, DeMatteo RP, Blumgart LH, and Jarnagin WR. Optimal abdominal incision for partial hepatectomy: Increased late complications with Mercedes-type incisions compared to extended right subcostal incisions. *World Journal of Surgery*. 2006. 30(3): p. 410-418.
85. Mullerad M, Eisenberg DP, Akhurst TJ, Adusumilli PS, Riedl CC, Bhargava A, **Gönen M**, Finn R, Scardino PT, and Fong Y. Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus. *Molecular Imaging and Biology*. 2006. 8(1): p. 30-35.
86. Rizk N, Downey RJ, Akhurst T, **Gönen M**, Bains MS, Larson S, and Rusch V. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. *Annals of Thoracic Surgery*. 2006. 81(3): p. 1076-1081.
87. Flores RM, Akhurst T, **Gönen M**, Zakowski M, Dycoco J, Larson SM, and Rusch VW. Positron emission tomography predicts survival in malignant pleural mesothelioma. *Journal of Thoracic and Cardiovascular Surgery*. 2006. 132(4): p. 763-768.
88. Are C, **Gönen M**, D'Angelica M, DeMatteo RP, Fong Y, Blumgart LH, and Jarnagin WR. Differential diagnosis of proximal biliary obstruction. *Surgery*. 2006. 140(5): p. 756-763.
89. Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, **Gönen M**, Ebricht MI, Culliford A, Gusani NJ, and Fong Y. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. *Cancer Gene Therapy*. 2006. 13(3): p. 326-334.

90. Budak-Alpdogan T, Przybylowski M, **Gönen M**, Sadelain M, Bertino J, and Rivière I. Functional assessment of the engraftment potential of gammaretrovirus- modified CD34 + cells, using a short serum-free transduction protocol. *Human Gene Therapy*. 2006. 17(7): p. 780-794.
91. Brenner B, Shah MA, Karpeh MS, **Gönen M**, Brennan MF, Coit DG, Klimstra DS, Tang LH, and Kelsen DP. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. *Annals of Oncology*. 2006. 17(9): p. 1404-1411.
92. Grobmyer SR, Wang L, **Gönen M**, Fong Y, Klimstra D, D'Angelica M, DeMatteo RP, Schwartz L, Blumgart LH, and Jarnagin WR. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. *Annals of Surgery*. 2006. 244(2): p. 260-264.
93. Fong Y, Wagman L, **Gönen M**, Crawford J, Reed W, Swanson R, Pan C, Ritchey J, Stewart A, and Choti M. Evidence-based gallbladder cancer staging: Changing cancer staging by analysis of data from the national cancer database. *Annals of Surgery*. 2006. 243(6): p. 767-771.
94. Allen PJ, D'Angelica M, **Gönen M**, Jaques DP, Coit DG, Jarnagin WR, DeMatteo R, Fong Y, Blumgart LH, and Brennan MF. A selective approach to the resection of cystic lesions of the pancreas: Results from 539 consecutive patients. *Annals of Surgery*. 2006. 244(4): p. 572-579.
95. Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, **Gönen M**, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, and O'Connor OA. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response? *British Journal of Haematology*. 2006. 134(4): p. 391-398.
96. Toner LE, Vrhovac R, Smith EA, Gardner J, Heaney M, **Gönen M**, Teruya-Feldstein J, Sirotiak F, and O'Connor OA. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-hodgkin's lymphoma. *Clinical Cancer Research*. 2006. 12(3 I): p. 924-932.
97. Jarnagin WR, Klimstra DS, Hezel M, **Gönen M**, Fong Y, Roggin K, Cymes K, Dematteo RP, D'Angelica M, Blumgart LH, and Singh B. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: Correlation with anatomic site, pathologic variables, and clinical outcome. *Journal of Clinical Oncology*. 2006. 24(7): p. 1152-1160.
98. Robbins RJ, Wan Q, Grewal RK, Reibke R, **Gönen M**, Strauss HW, Tuttle RM, Drucker W, and Larson SM. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *Journal of Clinical Endocrinology and Metabolism*. 2006. 91(2): p. 498-505.
99. Brady MS, Akhurst T, Spanknebel K, Hilton S, **Gönen M**, Patel A, and Larson S. Utility of preoperative [(18)F] Fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. *Annals of Surgical Oncology*. 2006. 13(4): p. 525-532.
100. Port ER, Yeung H, **Gönen M**, Liberman L, Caravelli J, Borgen P, and Larson S. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in

- selected patients with high-risk, operable breast carcinoma. *Annals of Surgical Oncology*. 2006. 13(5): p. 677-684.
101. Yoon SS, Kim SH, **Gönen M**, Heffernan NM, Detwiler KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK, and DeMatteo RP. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. *Annals of Surgical Oncology*. 2006. 13(3): p. 353-362.
 102. Schöder H and **Gönen M**. Screening for cancer with PET and PET/CT: Potential and limitations. *Journal of Nuclear Medicine*. 2007. 48(1 SUPPL.): p. 4S-18S.
 103. Yeh JJ, **Gönen M**, Tomlinson JS, Idrees K, Brennan MF, and Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. *British Journal of Surgery*. 2007. 94(4): p. 466-472.
 104. Park JO, **Gönen M**, D'Angelica MI, Dematteo RP, Fong Y, Wuest D, Blumgart LH, and Jarnagin WR. Autologous versus allogeneic transfusions: No difference in perioperative outcome after partial hepatectomy: Autologous transfusion on hepatectomy outcome. *Journal of Gastrointestinal Surgery*. 2007. 11(10): p. 1286-1293.
 105. House MG, **Gönen M**, Jarnagin WR, D'Angelica M, Dematteo RP, Fong Y, Brennan MF, and Allen PJ. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. *Journal of Gastrointestinal Surgery*. 2007. 11(11): p. 1549-1555.
 106. Dalal KM, Woo Y, Galanis C, **Gönen M**, Tang L, Allen P, Dematteo R, Fong Y, and Coit DG. Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction. *Journal of Gastrointestinal Surgery*. 2007. 11(12): p. 1598-1606.
 107. Parks R, **Gönen M**, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, Garden OJ, Blumgart LH, and Fong Y. Adjuvant Chemotherapy Improves Survival after Resection of Hepatic Colorectal Metastases: Analysis of Data from Two Continents. *Journal of the American College of Surgeons*. 2007. 204(5): p. 753-761.
 108. Miller G, Biernacki P, Kemeny NE, **Gönen M**, Downey R, Jarnagin WR, D'Angelica M, Fong Y, Blumgart LH, and DeMatteo RP. Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases. *Journal of the American College of Surgeons*. 2007. 205(2): p. 231-238.
 109. Downey RJ, Akhurst T, **Gönen M**, Park B, and Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. *Journal of Thoracic and Cardiovascular Surgery*. 2007. 133(6): p. 1419-1427.e4.
 110. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, **Gönen M**, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, and Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. *Lancet Oncology*. 2007. 8(4): p. 304-310.
 111. Lassmann S, Tang L, Capanu M, Brabletz T, Schöpflin A, Zur Hausen A, **Gönen M**, Kemeny N, Shia J, Klimstra D, and Werner M. Predictive Molecular Markers for Colorectal Cancer Patients With Resected Liver Metastasis and Adjuvant Chemotherapy. *Gastroenterology*. 2007. 133(6): p. 1831-1839.

112. DeMatteo RP, Maki RG, Singer S, **Gönen M**, Brennan MF, and Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. *Annals of Surgery*. 2007. 245(3): p. 347-352.
113. Barbour AP, Rizk NP, **Gönen M**, Tang L, Bains MS, Rusch VW, Coit DG, and Brennan MF. Adenocarcinoma of the gastroesophageal junction: Influence of esophageal resection margin and operative approach on outcome. *Annals of Surgery*. 2007. 246(1): p. 1-8.
114. Are C, **Gönen M**, Zazzali K, DeMatteo RP, Jarnagin WR, Fong Y, Blumgart LH, and D'Angelica M. The impact of margins on outcome after hepatic resection for colorectal metastasis. *Annals of Surgery*. 2007. 246(2): p. 295-300.
115. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, **Gönen M**, Kemeny N, Brennan MF, Blumgart LH, and D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *Journal of Clinical Oncology*. 2007. 25(29): p. 4575-4580.
116. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, **Gönen M**, Quinones M, Morse M, and Chen HX. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. *Journal of Clinical Oncology*. 2007. 25(29): p. 4557-4561.
117. Ferrone CR, Tang LH, Tomlinson J, **Gönen M**, Hochwald SN, Brennan MF, Klimstra DS, and Allen PJ. Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? *Journal of Clinical Oncology*. 2007. 25(35): p. 5609-5615.
118. Kornprat P, Jarnagin WR, **Gönen M**, DeMatteo RP, Fong Y, Blumgart LH, and D'Angelica M. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. *Annals of Surgical Oncology*. 2007. 14(3): p. 1151-1160.
119. D'Angelica M, Kornprat P, **Gönen M**, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, and Saltz LB. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. *Annals of Surgical Oncology*. 2007. 14(2): p. 759-765.
120. Barbour AP, Rizk NP, **Gönen M**, Tang L, Bains MS, Rusch VW, Coit DG, and Brennan MF. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): Impact of adequate staging on outcome. *Annals of Surgical Oncology*. 2007. 14(2): p. 306-316.
121. Gold JS, Van Der Zwan SM, **Gönen M**, Maki RG, Singer S, Brennan MF, Antonescu CR, and DeMatteo RP. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. *Annals of Surgical Oncology*. 2007. 14(1): p. 134-142.
122. Gold JS, Van Der Zwan SM, **Gönen M**, Maki RG, Singer S, Brennan MF, Antonescu CR, and DeMatteo RP. Erratum: Outcome of metastatic GIST in the era before tyrosine kinase inhibitors (*Annals of Surgical Oncology* DOI: 10.1245/s10434-006-9177-7). *Annals of Surgical Oncology*. 2007. 14(10): p. 3027.
123. Strong VE, D'Angelica M, Tang L, Prete F, **Gönen M**, Coit D, Touijer KA, Fong Y, and Brennan MF. Laparoscopic adrenalectomy for isolated adrenal metastasis. *Annals of Surgical Oncology*. 2007. 14(12): p. 3392-3400.

124. Gold JS, Tang LH, **Gönen M**, Coit DG, Brennan MF, and Allen PJ. Utility of a prognostic nomogram designed for gastric cancer in predicting outcome of patients with R0 resected duodenal adenocarcinoma. *Annals of Surgical Oncology*. 2007. 14(11): p. 3159-3167.
125. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, **Gönen M**, Kelsen DP, Brennan MF, and Coit DG. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? *Annals of Surgical Oncology*. 2007. 14(12): p. 3412-3418.
126. Sofocleous CT, Nascimento RG, **Gönen M**, Theodoulou M, Covey AM, Brody LA, Solomon SM, Thornton R, Fong Y, Getrajdman GI, and Brown KT. Radiofrequency ablation in the management of liver metastases from breast cancer. *American Journal of Roentgenology*. 2007. 189(4): p. 883-889.
127. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, **Gönen M**, Shaha AR, Tuttle RM, Shah JP, and Larson SM. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. *Journal of Nuclear Medicine*. 2007. 48(4): p. 501-507.
128. DeMatteo RP, Gold JS, Saran L, **Gönen M**, Kui HL, Maki RG, Singer S, Besmer P, Brennan MF, and Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). *Cancer*. 2008. 112(3): p. 608-615.
129. Quah HM, Chou JF, **Gönen M**, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, and Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. *Cancer*. 2008. 113(1): p. 57-64.
130. Ghosh P and **Gönen M**. Bayesian modeling of multivariate average bioequivalence. *Statistics in Medicine*. 2008. 27(13): p. 2402-2419.
131. Dalal KM, Woo Y, Kelly K, Galanis C, **Gönen M**, Fong Y, and Coit DG. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. *Gastric Cancer*. 2008. 11(4): p. 206-213.
132. Quah HM, Chou JF, **Gönen M**, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, and Weiser MR. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. *Diseases of the Colon and Rectum*. 2008. 51(5): p. 503-507.
133. Ferrone CR, Brennan MF, **Gönen M**, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, and Allen PJ. Pancreatic adenocarcinoma: The actual 5-year survivors. *Journal of Gastrointestinal Surgery*. 2008. 12(4): p. 701-706.
134. House MG, Fong Y, Arnaoutakis DJ, Sharma R, Winston CB, Protic M, **Gönen M**, Olson SH, Kurtz RC, Brennan MF, and Allen PJ. Preoperative predictors for complications after pancreaticoduodenectomy: Impact of BMI and body fat distribution. *Journal of Gastrointestinal Surgery*. 2008. 12(2): p. 270-278.
135. Vickers AJ, Bianco FJ, **Gönen M**, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, and Scardino PT. Effects of Pathologic Stage on the Learning Curve for Radical Prostatectomy: Evidence That Recurrence in Organ-Confined Cancer Is Largely Related to Inadequate Surgical Technique. *European Urology*. 2008. 53(5): p. 960-966.

136. Shia J, Klimstra DS, Nitzkowski JR, Low PS, **Gönen M**, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, and Paty PB. Immunohistochemical expression of folate receptor α in colorectal carcinoma: patterns and biological significance. *Human Pathology*. 2008. 39(4): p. 498-505.
137. Cho CS, **Gönen M**, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D'Angelica MI, Blumgart LH, and DeMatteo RP. A Novel Prognostic Nomogram Is More Accurate than Conventional Staging Systems for Predicting Survival after Resection of Hepatocellular Carcinoma. *Journal of the American College of Surgeons*. 2008. 206(2): p. 281-291.
138. White R, Winston C, **Gönen M**, D'Angelica M, Jarnagin W, Fong Y, Conlon K, Brennan M, and Allen P. Current Utility of Staging Laparoscopy for Pancreatic and Peripancreatic Neoplasms. *Journal of the American College of Surgeons*. 2008. 206(3): p. 445-450.
139. Kattan MW and **Gönen M**. The prediction philosophy in statistics. *Urologic Oncology: Seminars and Original Investigations*. 2008. 26(3): p. 316-319.
140. Allen PJ, Reiner AS, **Gönen M**, Klimstra DK, Blumgart LH, Brennan MF, D'Angelica M, Dematteo R, Fong Y, and Jarnagin WR. Extrahepatic cholangiocarcinoma: A comparison of patients with resected proximal and distal lesions. *HPB*. 2008. 10(5): p. 341-346.
141. Elkin EB, Ishill N, Riley GF, Bach PB, **Gönen M**, Begg CB, and Schrag D. Disenrollment from medicare managed care among beneficiaries with and without a cancer diagnosis. *Journal of the National Cancer Institute*. 2008. 100(14): p. 1013-1021.
142. Greco C, Nehmeh SA, Schöder H, **Gönen M**, Raphael B, Stambuk HE, Humm JL, Larson SM, and Lee NY. Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*. 2008. 31(5): p. 439-445.
143. Kattan MW, **Gönen M**, Jarnagin WR, DeMatteo R, D'Angelica M, Weiser M, Blumgart LH, and Fong Y. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. *Annals of Surgery*. 2008. 247(2): p. 282-287.
144. Ito H, Are C, **Gönen M**, D'Angelica M, DeMatteo RP, Kemeny NE, Fong Y, Blumgart LH, and Jarnagin WR. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. *Annals of Surgery*. 2008. 247(6): p. 994-1002.
145. D'Angelica M and **Gönen M**. Impact of margin width on outcome after resection of colorectal liver metastases [4]. *Annals of Surgery*. 2008. 247(5): p. 905-906.
146. Endo I, **Gönen M**, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, Dematteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, and Jarnagin WR. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. *Annals of Surgery*. 2008. 248(1): p. 84-96.
147. Jarnagin WR, **Gönen M**, Maithel SK, Fong Y, Dangelica MI, Dematteo RP, Grant F, Wuest D, Kundu K, Blumgart LH, and Fischer M. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. *Annals of Surgery*. 2008. 248(3): p. 360-368.
148. Gold JS, Are C, Kornprat P, Jarnagin WR, **Gönen M**, Fong Y, DeMatteo RP, Blumgart LH, and D'Angelica M. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic

- outcome: Trends in treatment over time in 440 patients. *Annals of Surgery*. 2008. 247(1): p. 109-117.
149. Sofocleous CT, Nascimento RG, Petrovic LM, Klimstra DS, **Gönen M**, Brown KT, Brody LA, Covey AM, Thornton RH, Fong Y, Solomon SB, Schwartz LH, Dematteo RP, and Getrajdman GI. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: Initial results 1. *Radiology*. 2008. 249(1): p. 364-374.
150. Sawai A, Chandarlapaty S, Greulich H, **Gönen M**, Ye Q, Arteaga CL, Sellers W, Rosen N, and Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. *Cancer Research*. 2008. 68(2): p. 589-596.
151. Tse AN, Klimstra DS, **Gönen M**, Shah M, Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, Chung K, Maki R, Lefkowitz R, Brown K, Manova-Todorova K, Wu N, Egorin MJ, Kelsen D, and Schwartz GK. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. *Clinical Cancer Research*. 2008. 14(20): p. 6704-6711.
152. Paoluzzi L, **Gönen M**, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, and O'Connor OA. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. *Blood*. 2008. 111(11): p. 5350-5358.
153. Paoluzzi L, **Gönen M**, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, and O'Connor OA. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. *Blood*. 2008. 112(7): p. 2906-2916.
154. Vickers AJ, Cronin AM, Elkin EB, and **Gönen M**. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *BMC Medical Informatics and Decision Making*. 2008. 8.
155. Weiser MR, Landmann RG, Kattan MW, **Gönen M**, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, and Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. *Journal of Clinical Oncology*. 2008. 26(3): p. 380-385.
156. **Gönen M**. Area between curves: What you see is not what you get. *Journal of Clinical Oncology*. 2008. 26(13): p. 2236.
157. Endo I, House MG, Klimstra DS, **Gönen M**, D'Angelica M, DeMatteo RP, Fong Y, Blumgart LH, and Jarnagin WR. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. *Annals of Surgical Oncology*. 2008. 15(8): p. 2104-2112.
158. Barbour AP, Jones M, **Gönen M**, Gotley DC, Thomas J, Thomson DB, Burmeister B, and Smithers BM. Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response. *Annals of Surgical Oncology*. 2008. 15(10): p. 2894-2902.
159. Maithel SK, Maloney S, Winston C, **Gönen M**, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, and Allen PJ. Preoperative CA 19-9 and the yield of staging laparoscopy in

- patients with radiographically resectable pancreatic adenocarcinoma. *Annals of Surgical Oncology*. 2008. 15(12): p. 3512-3520.
160. Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, **Gönen M**, Scher HI, Larson SM, and Divgi CR. Antibody mass escalation study in patients with castration-resistant prostate cancer using ¹¹¹In-J591: Lesion detectability and dosimetric projections for ⁹⁰Y radioimmunotherapy. *Journal of Nuclear Medicine*. 2008. 49(7): p. 1066-1074.
161. Silberhumer GR, Zakian K, Malhotra S, Brader P, **Gönen M**, Koutcher J, and Fong Y. Relationship between ³¹P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts. *British Journal of Surgery*. 2009. 96(7): p. 809-816.
162. Vickers AJ, Cronin AM, Kattan MW, **Gönen M**, Scardino PT, Milowsky MI, Dalbagni G, and Bchner BH. Clinical benefits of a multivariate prediction model for bladder cancer: A decision analytic approach. *Cancer*. 2009. 115(23): p. 5460-5469.
163. Nash GM, Weiser MR, Guillem JG, Temple LK, Shia J, **Gönen M**, Wong WD, and Paty PB. Long-term survival after transanal excision of T1 rectal cancer. *Diseases of the Colon and Rectum*. 2009. 52(4): p. 577-582.
164. Moskowitz CS, Jia X, Schwartz LH, and **Gönen M**. A simulation study to evaluate the impact of the number of lesions measured on response assessment. *European Journal of Cancer*. 2009. 45(2): p. 300-310.
165. Auer RC, Schulman AR, Tuorto S, **Gönen M**, Gonsalves J, Schwartz L, Ginsberg MS, and Fong Y. Use of Helical CT Is Associated with an Increased Incidence of Postoperative Pulmonary Emboli in Cancer Patients with No Change in the Number of Fatal Pulmonary Emboli. *Journal of the American College of Surgeons*. 2009. 208(5): p. 871-878.
166. Gold JS, **Gönen M**, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, and DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. *The Lancet Oncology*. 2009. 10(11): p. 1045-1052.
167. Can AS, Bersot TP, and **Gönen M**. Anthropometric indices and their relationship with cardiometabolic risk factors in a sample of Turkish adults. *Public Health Nutrition*. 2009. 12(4): p. 538-546.
168. Noy A, Schöder H, **Gönen M**, Weissler M, Ertelt K, Cohler C, Portlock C, Hamlin P, and Yeung HWD. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). *Annals of Oncology*. 2009. 20(3): p. 508-512.
169. Jarnagin WR, Schwartz LH, Gultekin DH, **Gönen M**, Haviland D, Shia J, D'Angelica M, Fong Y, DeMatteo R, Tse A, Blumgart LH, and Kemeny N. Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. *Annals of Oncology*. 2009. 20(9): p. 1589-1595.
170. Jhaver M, Coit D, Brennan M, Qin LX, **Gönen M**, Klimstra D, Tang L, Kelsen DP, and Shah MA. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: Gene expression analysis with pathologic validation. *American Journal of Clinical Oncology: Cancer Clinical Trials*. 2009. 32(4): p. 356-363.

171. Sima CS, Jarnagin WR, Fong Y, Elkin E, Fischer M, Wuest D, D'Angelica M, Dematteo RP, Blumgart LH, and **Gönen M**. Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. *Annals of Surgery*. 2009. 250(6): p. 914-921.
172. Katz SC, Shia J, Liau KH, **Gönen M**, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, and Dematteo RP. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. *Annals of Surgery*. 2009. 249(4): p. 617-623.
173. O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, **Gönen M**, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, and Winter J. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial. *British Journal of Haematology*. 2009. 145(1): p. 34-39.
174. Rathkopf D, Dickson MA, Feldman DR, Carvajal RD, Shah MA, Wu N, Lefkowitz R, **Gönen M**, Cane LM, Dials HJ, Winkelmann JL, Bosl GJ, and Schwartz GK. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. *Clinical Cancer Research*. 2009. 15(23): p. 7405-7411.
175. Carvajal RD, Tse A, Shah MA, Lefkowitz RA, **Gönen M**, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, and O'Reilly EM. A phase II study of flavopiridol (alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. *Pancreatology*. 2009. 9(4): p. 404-409.
176. Sofocleous CT, Petre N, Manova-Todorova K, Petrovic L, and **Gönen M**. Re: Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours. *Digestive Surgery*. 2009. 26(5): p. 434-435.
177. **Gönen M**. Bayesian clinical trials: No more excuses. *Clinical Trials*. 2009. 6(3): p. 203-204.
178. Miksad RA, **Gönen M**, Lynch TJ, and Roberts Jr TG. Interpreting trial results in light of conflicting evidence: A bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. *Journal of Clinical Oncology*. 2009. 27(13): p. 2245-2252.
179. **Gönen M**, Schrag DM, and Weiser MR. Nodal staging score: A tool to assess adequate staging of node-negative colon cancer. *Journal of Clinical Oncology*. 2009. 27(36): p. 6166-6171.
180. Ariyan C, Brady MS, **Gönen M**, Busam K, and Coit D. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. *Annals of Surgical Oncology*. 2009. 16(1): p. 186-190.
181. Fahy BN, D'Angelica M, Dematteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, **Gönen M**, and Jarnagin WR. Synchronous hepatic metastases from colon cancer: Changing treatment strategies and results of surgical intervention. *Annals of Surgical Oncology*. 2009. 16(2): p. 361-370.
182. Strong VE, Devaud N, Allen PJ, **Gönen M**, Brennan MF, and Coit D. Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: A case-control study. *Annals of Surgical Oncology*. 2009. 16(6): p. 1507-1513.

183. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, **Gönen M**, Blumgart L, and D'Angelica M. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: Results in 127 patients treated at a single center. *Annals of Surgical Oncology*. 2009. 16(8): p. 2138-2146.
184. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, **Gönen M**, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, and DeMatteo RP. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. *Annals of Surgical Oncology*. 2009. 16(9): p. 2524-2530.
185. Kelly KJ, Wong J, Gladdy R, Moore-Dalal K, Woo Y, **Gönen M**, Brennan M, Allen P, Fong Y, and Coit D. Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. *Annals of Surgical Oncology*. 2009. 16(12): p. 3333-3339.
186. Grewal RK, Larson SM, Pentlow CE, Pentlow KS, **Gönen M**, Qualey R, Natbony L, and Tuttle RM. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. *Journal of Nuclear Medicine*. 2009. 50(10): p. 1605-1610.
187. Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP, **Gönen M**, Young JW, and DeMatteo RP. Human liver dendritic cells promote T cell hyporesponsiveness. *Journal of Immunology*. 2009. 182(4): p. 1901-1911.
188. Osborne JR, Port E, **Gönen M**, Doane A, Yeung H, Gerald W, Cook JB, and Larson S. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2010. 51(4): p. 543-550.
189. Morris K, Tuorto S, **Gönen M**, Schwartz L, DeMatteo R, D'Angelica M, Jarnagin WR, and Fong Y. Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. *Archives of Surgery*. 2010. 145(11): p. 1069-1073.
190. Neuman HB, Morrogh M, **Gönen M**, Van Zee KJ, Morrow M, and King TA. Stage IV breast cancer in the era of targeted therapy: Does surgery of the primary tumor matter? *Cancer*. 2010. 116(5): p. 1226-1233.
191. Chou JF, Row D, **Gönen M**, Liu YH, Schrag D, and Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: A population-based study. *Cancer*. 2010. 116(11): p. 2560-2570.
192. Morrogh M, Miner TJ, Park A, Jenckes A, **Gönen M**, Seidman A, Morrow M, Jaques DP, and King TA. A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer. *Cancer*. 2010. 116(14): p. 3338-3347.
193. Olson SH, Chou JF, Ludwig E, O'Reilly E, Allen PJ, Jarnagin WR, Bayuga S, Simon J, **Gönen M**, Reisacher WR, and Kurtz RC. Allergies, obesity, other risk factors and survival from pancreatic cancer. *International Journal of Cancer*. 2010. 127(10): p. 2412-2419.
194. **Gönen M**. The Bayesian t-test and beyond. *Methods in molecular biology (Clifton, N.J.)*. 2010. 620: p. 179-199.
195. **Gönen M**, Schrag D, and Weiser MR. Nodal staging score: A tool to assess adequate staging of node-negative colon cancer. *Diseases of the Colon and Rectum*. 2010. 53(7): p. 1101.

196. Nash GM, Weiss A, Dasgupta R, **Gönen M**, Guillem JG, and Wong WD. Close distal margin and rectal cancer recurrence after sphincter-preserving rectal resection. *Diseases of the Colon and Rectum*. 2010. 53(10): p. 1365-1373.
197. Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, **Gönen M**, Schwartz GK, Kern SE, Zabludoff S, and Brassil PJ. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. *Cancer Chemotherapy and Pharmacology*. 2010. 66(2): p. 245-254.
198. Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, **Gönen M**, Cane LM, Dials HJ, and Schwartz GK. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. *Cancer Chemotherapy and Pharmacology*. 2010. 66(6): p. 1113-1121.
199. House MG, Ito H, **Gönen M**, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, and D'Angelica MI. Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution. *Journal of the American College of Surgeons*. 2010. 210(5): p. 744-752.
200. Jayaraman S, **Gönen M**, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, and Allen PJ. Laparoscopic distal pancreatectomy: Evolution of a technique at a single institution. *Journal of the American College of Surgeons*. 2010. 211(4): p. 503-509.
201. Selçuk Can A, Akal Yildiz E, Samur G, Rakcoğlu N, Pekcan G, Özbayrakçı S, Palaoğlu KE, **Gönen M**, and Bersot TP. Optimal waist:height ratio cut-off point for cardiometabolic risk factors in Turkish adults. *Public Health Nutrition*. 2010. 13(4): p. 488-495.
202. Moreira AL, **Gönen M**, Rekhtman N, and Downey RJ. Progenitor stem cell marker expression by pulmonary carcinomas. *Modern Pathology*. 2010. 23(6): p. 889-895.
203. **Gönen M** and Weiser MR. Whither TNM? *Seminars in Oncology*. 2010. 37(1): p. 27-30.
204. Schmidlein CR, Beattie BJ, Bailey DL, Akhurst TJ, Wang W, **Gönen M**, Kirov AS, and Humm JL. Using an external gating signal to estimate noise in PET with an emphasis on tracer avid tumors. *Physics in Medicine and Biology*. 2010. 55(20): p. 6299-6326.
205. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, **Gönen M**, Brokhin M, Omry G, Fagin JA, and Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. *Thyroid*. 2010. 20(12): p. 1341-1349.
206. Babur Ö, Demir E, **Gönen M**, Sander C, and Dogrusoz U. Discovering modulators of gene expression. *Nucleic Acids Research*. 2010. 38(17): p. 5648-5656.
207. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, **Gönen M**, Obuchowski N, Pencina MJ, and Kattan MW. Assessing the performance of prediction models: A framework for traditional and novel measures. *Epidemiology*. 2010. 21(1): p. 128-138.
208. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, **Gönen M**, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, Otoole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, and Yao J. Pathology reporting of neuroendocrine tumors: Application of the delphic consensus process to the development

- of a minimum pathology data set. *American Journal of Surgical Pathology*. 2010. 34(3): p. 300-313.
209. Ito K, Ito H, Allen PJ, **Gönen M**, Klimstra D, D'Angelica MI, Fong Y, Dematteo RP, Brennan MF, Blumgart LH, and Jarnagin WR. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. *Annals of Surgery*. 2010. 251(4): p. 675-681.
210. Strong VE, Song KY, Park CH, Jacks LM, **Gönen M**, Shah M, Coit DG, and Brennan MF. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. *Annals of Surgery*. 2010. 251(4): p. 640-646.
211. Fischer M, Matsuo K, **Gönen M**, Grant F, Dematteo RP, D'Angelica MI, Mascarenhas J, Brennan MF, Allen PJ, Blumgart LH, and Jarnagin WR. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: Results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. *Annals of Surgery*. 2010. 252(6): p. 952-958.
212. Katz SC, Donkor C, Glasgow K, Pillarisetty VG, **Gönen M**, Espat NJ, Klimstra DS, D'Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, and Tang LH. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. *HPB*. 2010. 12(10): p. 674-683.
213. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, **Gönen M**, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Cortelli BMG, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, and Vose J. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. *Clinical Cancer Research*. 2010. 16(2): p. 719-726.
214. Meirelles GSP, Schöder H, Ravizzini GC, **Gönen M**, Fox JJ, Humm J, Morris MJ, Scher HI, and Larson SM. Prognostic value of baseline [¹⁸F] fluorodeoxyglucose positron emission tomography and ^{99m}Tc-MDP bone scan in progressing metastatic prostate cancer. *Clinical Cancer Research*. 2010. 16(24): p. 6093-6099.
215. Silberhumer GR, Brader P, Wong J, Serganova IS, **Gönen M**, Gonzalez SJ, Blasberg R, Zamarin D, and Fong Y. Genetically engineered oncolytic newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. *Molecular Cancer Therapeutics*. 2010. 9(10): p. 2761-2769.
216. Park SY, **Gönen M**, Kim HJ, Michor F, and Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. *Journal of Clinical Investigation*. 2010. 120(2): p. 636-644.
217. Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, **Gönen M**, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, and Levine RL. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. *Journal of Clinical Investigation*. 2010. 120(10): p. 3578-3593.
218. **Gönen M** and Heller G. Lehmann family of ROC curves. *Medical Decision Making*. 2010. 30(4): p. 509-517.
219. Robson PC, Heffernan N, **Gönen M**, Thornton R, Brody LA, Holmes R, Brown KT, Covey AM, Fleischer D, Getrajdman GI, Jarnagin W, Sofocleous C, Blumgart L, and D'Angelica M.

- Prospective study of outcomes after percutaneous biliary drainage for malignant biliary obstruction. *Annals of Surgical Oncology*. 2010. 17(9): p. 2303-2311.
220. Feeney J, Horwitz S, **Gönen M**, and Schöder H. Characterization of T-cell lymphomas by FDG PET/CT. *American Journal of Roentgenology*. 2010. 195(2): p. 333-340.
221. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, **Gönen M**, Strauss HW, Larson SM, and Schöder H. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. *Journal of Nuclear Medicine*. 2010. 51(9): p. 1361-1367.
222. Singnurkar A, Solomon SB, **Gönen M**, Larson SM, and Schöder H. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. *Journal of Nuclear Medicine*. 2010. 51(12): p. 1833-1840.
223. Vickers AJ, Cronin AM, Kattan MW, **Gönen M**, Scardino PT, Milowsky MI, Dalbagni G, Bchner BH, Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, and Tseng JF. Erratum: Clinical benefits of a multivariate prediction model for bladder cancer: A decision analytic approach (*Cancer* (2009) 115 (5460-5469)). *Cancer*. 2011. 117(16): p. 3867.
224. Qi J, Shukla-Dave A, Fong Y, **Gönen M**, Schwartz LH, Jarnagin WM, Koutcher JA, and Zakian KL. 31P MR spectroscopic imaging detects regenerative changes in human liver stimulated by portal vein embolization. *Journal of Magnetic Resonance Imaging*. 2011. 34(2): p. 336-344.
225. Ghosh P, Nathoo F, **Gönen M**, and Tiwari RC. Assessing noninferiority in a three-arm trial using the Bayesian approach. *Statistics in Medicine*. 2011. 30(15): p. 1795-1808.
226. González SJ, Wong J, González L, Brader P, Zakowski M, **Gönen M**, Fong Y, and Strong VE. Novel handheld PET probes provide intraoperative localization of PET-avid lymph nodes. *Surgical Endoscopy and Other Interventional Techniques*. 2011. 25(10): p. 3214-3221.
227. Comen E, Balistreri L, **Gönen M**, Dutra-Clarke A, Fazio M, Vijai J, Stadler Z, Kauff N, Kirchoff T, Hudis C, Offit K, and Robson M. Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. *Breast Cancer Research and Treatment*. 2011. 127(2): p. 479-487.
228. Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, **Gönen M**, Cane LM, Dials HJ, and Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. *Investigational New Drugs*. 2011. 29(5): p. 1004-1012.
229. Butte JM, Brennan MF, **Gönen M**, Tang LH, D'Angelica MI, Fong Y, DeMatteo RP, Jarnagin WR, and Allen PJ. Solid pseudopapillary tumors of the pancreas. clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. *Journal of Gastrointestinal Surgery*. 2011. 15(2): p. 350-357.
230. González SJ, González L, Wong J, Brader P, Zakowski M, **Gönen M**, Daghighian F, Fong Y, and Strong VE. An analysis of the utility of handheld PET probes for the intraoperative localization of malignant tissue. *Journal of Gastrointestinal Surgery*. 2011. 15(2): p. 358-366.
231. Terezakis SA, Hunt MA, Kowalski A, McCann P, Schmidtlein CR, Reiner A, **Gönen M**, Kirov AS, Gonzales AM, Schöder H, and Yahalom J. [18F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of

- lymphoma and hematologic malignancies. *International Journal of Radiation Oncology Biology Physics*. 2011. 81(3): p. 615-622.
232. Gaujoux S, Brennan MF, **Gönen M**, D'Angelica MI, DeMatteo R, Fong Y, Schattner M, DiMaio C, Janakos M, Jarnagin WR, and Allen PJ. Cystic lesions of the pancreas: Changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. *Journal of the American College of Surgeons*. 2011. 212(4): p. 590-600.
233. Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, **Gönen M**, Zanzonico P, Smith-Jones P, and Larson SM. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. *Journal of Controlled Release*. 2011. 149(3): p. 292-298.
234. Sofocleous CT, Petre EN, **Gönen M**, Brown KT, Solomon SB, Covey AM, Alago W, Brody LA, Thornton RH, D'Angelica M, Fong Y, and Kemeny NE. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. *Journal of Vascular and Interventional Radiology*. 2011. 22(6): p. 755-761.
235. Butte JM, Do RK, Shia J, **Gönen M**, D'Angelica MI, Getrajdman GI, Allen PJ, Fong Y, Dematteo RP, Klimstra DS, and Jarnagin WR. Liver angiomyolipomas: A clinical, radiologic, and pathologic analysis of 22 patients from a single center. *Surgery*. 2011. 150(3): p. 557-567.
236. Can AS, Bersot TP, and **Gönen M**. Erratum: Anthropometric indices and their relationship with cardiometabolic risk factors in a sample of Turkish adults-Corrigendum (Public Health Nutrition DOI: 10.1017/S1368980008002474). *Public Health Nutrition*. 2011. 14(1): p. 189.
237. Fields RC, Strong VE, **Gönen M**, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, and Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. *British Journal of Cancer*. 2011. 104(12): p. 1840-1847.
238. D'Angelica M, Ammori J, **Gönen M**, Klimstra DS, Low PS, Murphy L, Weiser MR, Paty PB, Fong Y, Dematteo RP, Allen P, Jarnagin WR, and Shia J. Folate receptor- α expression in resectable hepatic colorectal cancer metastases: Patterns and significance. *Modern Pathology*. 2011. 24(9): p. 1221-1228.
239. **Gönen M**. Bias, biostatistics, and prognostic factors. *Journal of Thoracic Oncology*. 2011. 6(7 SUPPL. 3): p. S1705-S1709.
240. Shia J, Stadler Z, Weiser MR, Rentz M, **Gönen M**, Tang LH, Vakiani E, Katabi N, Xiong X, Markowitz AJ, Shike M, Guillem J, and Klimstra DS. Immunohistochemical staining for dna mismatch repair proteins in intestinal tract carcinoma: How reliable are biopsy samples? *American Journal of Surgical Pathology*. 2011. 35(3): p. 447-454.
241. Meirelles GSP, **Gönen M**, and Strauss HW. 18F-FDG uptake and calcifications in the thoracic aorta on positron emission tomography/computed tomography examinations: Frequency and stability on serial scans. *Journal of Thoracic Imaging*. 2011. 26(1): p. 54-62.
242. Sima CS, Jarnagin WR, and **Gönen M**. Reply. *Annals of Surgery*. 2011. 253(3): p. 632.
243. House MG, Kemeny NE, **Gönen M**, Fong Y, Allen PJ, Paty PB, Dematteo RP, Blumgart LH, Jarnagin WR, and D'Angelica MI. Comparison of adjuvant systemic chemotherapy with or

- without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. *Annals of Surgery*. 2011. 254(6): p. 851-856.
244. Nash GM, Row D, Weiss A, Shia J, Guillem JG, Paty PB, **Gönen M**, R. Weiser M, Temple LK, Fitzmaurice G, and Wong WD. A predictive model for lymph node yield in colon cancer resection specimens. *Annals of Surgery*. 2011. 253(2): p. 318-322.
245. Ito H, Ito K, D'Angelica M, **Gönen M**, Klimstra D, Allen P, Dematteo RP, Fong Y, Blumgart LH, and Jarnagin WR. Accurate staging for gallbladder cancer: Implications for surgical therapy and pathological assessment. *Annals of Surgery*. 2011. 254(2): p. 320-325.
246. Butte JM, **Gönen M**, Allen PJ, D'Angelica MI, Kingham TP, Fong Y, Dematteo RP, Blumgart L, and Jarnagin WR. The role of laparoscopic staging in patients with incidental gallbladder cancer. *HPB*. 2011. 13(7): p. 463-472.
247. Schwartz J, Humm JL, **Gönen M**, Kalaigian H, Schoder H, Larson SM, and Nehmeh SA. Repeatability of SUV measurements in serial PET. *Medical Physics*. 2011. 38(5): p. 2629-2638.
248. Dickson MA, Carvajal RD, Merrill Jr AH, **Gönen M**, Cane LM, and Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. *Clinical Cancer Research*. 2011. 17(8): p. 2484-2492.
249. Kemeny NE, Schwartz L, **Gönen M**, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, and Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results? *Oncology*. 2011. 80(3-4): p. 153-159.
250. Marotta LLC, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, **Gönen M**, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, and Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44 +CD24 - stem cell-like breast cancer cells in human tumors. *Journal of Clinical Investigation*. 2011. 121(7): p. 2723-2735.
251. Tang M, **Gönen M**, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, and Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. *Blood*. 2011. 118(6): p. 1622-1631.
252. Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mittra A, **Gönen M**, Zanzonico PB, Fong Y, and Szalay AA. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. *Journal of Translational Medicine*. 2011. 9.
253. Weiser MR, Gönen M, Chou JF, Kattan MW, and Schrag D. Predicting survival after curative colectomy for cancer: Individualizing colon cancer staging. *Journal of Clinical Oncology*. 2011. 29(36): p. 4796-4802.
254. Govindarajan A, Gönen M, Weiser MR, Shia J, Temple LK, Guillem JG, Paty PB, and Nash GM. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. *Journal of Clinical Oncology*. 2011. 29(34): p. 4568-4573.

255. Maker AV, Katabi N, **Gönen M**, Dematteo RP, D'Angelica MI, Fong Y, Jarnagin WR, Brennan MF, and Allen PJ. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. *Annals of Surgical Oncology*. 2011. 18(1): p. 199-206.
256. D'Angelica M, Kornprat P, **Gönen M**, DeMatteo RP, Fong Y, Blumgart LH, and Jarnagin WR. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. *Annals of Surgical Oncology*. 2011. 18(4): p. 1096-1103.
257. Mezhir JJ, **Gönen M**, Ammori JB, Strong VE, Brennan MF, and Coit DG. Treatment and outcome of patients with gastric remnant cancer after resection for peptic ulcer disease. *Annals of Surgical Oncology*. 2011. 18(3): p. 670-676.
258. Karakousis GC, Singer S, Zheng J, **Gönen M**, Coit D, Dematteo RP, and Strong VE. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): A size-matched comparison. *Annals of Surgical Oncology*. 2011. 18(6): p. 1599-1605.
259. Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, **Gönen M**, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, Dematteo RP, Allen PJ, and Jarnagin WR. Antiangiogenic therapy for primary liver cancer: Correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. *Annals of Surgical Oncology*. 2011. 18(8): p. 2192-2199.
260. Deodhar A, Dickfeld T, Single GW, Hamilton Jr WC, Thornton RH, Sofocleous CT, Maybody M, **Gönen M**, Rubinsky B, and Solomon SB. Irreversible electroporation near the heart: Ventricular arrhythmias can be prevented with ECG synchronization. *American Journal of Roentgenology*. 2011. 196(3): p. W330-W335.
261. Hambly NM, **Gönen M**, Gerst SR, Li D, Jia X, Mironov S, Sarasohn D, Fleming SE, and Hann LE. Implementation of evidence-based guidelines for thyroid nodule biopsy: A model for establishment of practice standards. *American Journal of Roentgenology*. 2011. 196(3): p. 655-660.
262. Sofocleous CT, May B, Petre EN, **Gönen M**, Thornton RH, Alago W, Rizk NP, Dupuy DE, and Solomon SB. Pulmonary thermal ablation in patients with prior pneumonectomy. *American Journal of Roentgenology*. 2011. 196(5): p. W606-W612.
263. Gerst S, Hann LE, Li D, **Gönen M**, Tickoo S, Sohn MJ, and Russo P. Evaluation of renal masses with contrast-enhanced ultrasound: Initial experience. *American Journal of Roentgenology*. 2011. 197(4): p. 897-906.
264. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, **Gönen M**, Panageas KS, Ritter G, Jungbluth AA, Old LJ, and Larson SM. 124I-huA33 antibody PET of colorectal cancer. *Journal of Nuclear Medicine*. 2011. 52(8): p. 1173-1180.
265. Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, **Gönen M**, Schöder H, Humm JL, Scher HI, and Larson SM. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. *Journal of Nuclear Medicine*. 2011. 52(11): p. 1727-1732.

266. Butte JM, **Gönen M**, Ding P, Goodman KA, Allen PJ, Nash GM, Guillem J, Paty PB, Saltz LB, Kemeny NE, Dematteo RP, Fong Y, Jarnagin WR, Weiser MR, and D'Angelica MI. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. *Cancer*. 2012. 118(21): p. 5414-5423.
267. Song TJ, Fong Y, Cho SJ, **Gönen M**, Hezel M, Tuorto S, Choi SY, Kim YC, Suh SO, Koo BH, Chae YS, Jarnagin WR, and Klimstra DS. Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. *Journal of Surgical Oncology*. 2012. 106(1): p. 84-88.
268. Grant FM, Protic M, **Gönen M**, Allen P, and Brennan MF. Intraoperative fluid management and complications following pancreatectomy. *Journal of Surgical Oncology*. 2012.
269. Strong VE, Song KY, Park CH, Jacks LM, **Gönen M**, Shah MA, Coit DG, and Brennan MF. Comparison of disease-specific survival in the United States and Korea after resection for early-stage node-negative gastric carcinoma. *Journal of Surgical Oncology*. 2012.
270. Qi J, Fong Y, Saltz L, D'Angelica MI, Kemeny NE, **Gönen M**, Shia J, Shukla-Dave A, Jarnagin WM, Do RKG, Schwartz LH, Koutcher JA, and Zakian KL. Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: A 1H MRS study. *NMR in Biomedicine*. 2012.
271. Vickers AJ, Cronin AM, and **Gönen M**. A simple decision analytic solution to the comparison of two binary diagnostic tests. *Statistics in Medicine*. 2012.
272. Seshan V, **Gönen M**, and Begg C. Comparing ROC curves derived from regression models. *Statistics in Medicine*. 2012.
273. Wang X, Sofocleous CT, Erinjeri JP, Petre EN, **Gönen M**, Do KG, Brown KT, Covey AM, Brody LA, Alago W, Thornton RH, Kemeny NE, and Solomon SB. Margin Size is an Independent Predictor of Local Tumor Progression After Ablation of Colon Cancer Liver Metastases. *CardioVascular and Interventional Radiology*. 2012: p. 1-10.
274. Wang X, Erinjeri JP, Jia X, **Gönen M**, Brown KT, Sofocleous CT, Getrajdman GI, Brody LA, Thornton RH, Maybody M, Covey AM, Siegelbaum RH, Alago W, and Solomon SB. Pattern of Retained Contrast on Immediate Postprocedure Computed tomography (CT) After Particle Embolization of Liver Tumors Predicts Subsequent Treatment Response. *CardioVascular and Interventional Radiology*. 2012: p. 1-9.
275. Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua Iii JL, **Gönen M**, Kuk D, Weiser M, Saltz L, Schrag D, Goodman K, Paty P, Guillem J, Nash GM, Temple L, Shia J, and Schwartz LH. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. *European Radiology*. 2012. 22(4): p. 821-831.
276. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, **Gönen M**, Schrag D, and Basch E. Reliability of adverse symptom event reporting by clinicians. *Quality of Life Research*. 2012. 21(7): p. 1159-1164.
277. Wong J, Kelly KJ, Mittra A, **Gönen M**, Allen P, Fong Y, and Coit D. RT-PCR Increases Detection of Submicroscopic Peritoneal Metastases in Gastric Cancer and Has Prognostic Significance. *Journal of Gastrointestinal Surgery*. 2012: p. 1-8.

278. Haeno H*, **Gönen M***, Davis MB, Herman JM, Iacobuzio-Donahue CA, and Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell*. 2012. 148(1-2): p. 362-375. (*: equal contribution)
279. Dikken JL, Van Grieken NCT, Krijnen P, **Gönen M**, Tang LH, Cats A, Verheij M, Brennan MF, Van De Velde CJH, and Coit DG. Preoperative chemotherapy does not influence the number of evaluable lymph nodes in resected gastric cancer. *European Journal of Surgical Oncology*. 2012. 38(4): p. 319-325.
280. Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, and **Gönen M**. Clinical nodal staging scores for bladder cancer: A proposal for preoperative risk assessment. *European Urology*. 2012. 61(2): p. 237-242.
281. Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joual A, Scherr DS, and **Gönen M**. Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. *European Urology*. 2012.
282. Hakimi AA, Chen YB, Wren J, **Gönen M**, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, and Hsieh JJ. Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. *European Urology*. 2012.
283. Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, Dematteo RP, **Gönen M**, Endo I, and Jarnagin WR. The blumgart preoperative staging system for hilar cholangiocarcinoma: Analysis of resectability and outcomes in 380 patients. *Journal of the American College of Surgeons*. 2012. 215(3): p. 343-355.
284. Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, **Gönen M**, and Shariat SF. Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. *Journal of Urology*. 2012.
285. Maithel SK, **Gönen M**, Ito H, Dematteo RP, Allen PJ, Fong Y, Blumgart LH, Jarnagin WR, and D'Angelica MI. Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. *Surgery*. 2012. 151(2): p. 162-170.
286. Gaujoux S, Tang L, Klimstra D, **Gönen M**, Brennan MF, D'Angelica M, Dematteo R, Fong Y, Jarnagin W, and Allen PJ. The outcome of resected cystic pancreatic endocrine neoplasms: A case-matched analysis. *Surgery*. 2012. 151(4): p. 518-525.
287. Song TJ, Haddad D, Adusumilli P, Kim T, Stiles B, Hezel M, Socci ND, **Gönen M**, and Fong Y. Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy. *Cancer Gene Therapy*. 2012. 19(1): p. 38-48.

288. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, **Gönen M**, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, and Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. *Nature*. 2012. 489(7414): p. 155-159.
289. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, **Gönen M**, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O, and Levine RL. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nature Genetics*. 2012. 44(11): p. 1179-1181.
290. Patel JP*, **Gönen M***, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, Van Den Brink MRM, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, and Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *New England Journal of Medicine*. 2012. 366(12): p. 1079-1089. (*: equal contribution)
291. Butte JM, Tang P, **Gönen M**, Shia J, Schattner M, Nash GM, Temple LKF, and Weiser MR. Rate of residual disease after complete endoscopic resection of malignant colonic polyp. *Diseases of the Colon and Rectum*. 2012. 55(2): p. 122-127.
292. Tang LH, **Gönen M**, Hedvat C, Modlin IM, and Klimstra DS. Objective quantification of the ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: A comparison of digital image analysis with manual methods. *American Journal of Surgical Pathology*. 2012. 36(12): p. 1761-1770.
293. Viñuela EF, **Gönen M**, Brennan MF, Coit DG, and Strong VE. Laparoscopic versus open distal gastrectomy for gastric cancer: A meta-analysis of randomized controlled trials and high-quality nonrandomized studies. *Annals of Surgery*. 2012. 255(3): p. 446-456.
294. Karkar AM, Tang LH, Kashikar ND, **Gönen M**, Solomon SB, Dematteo RP, D' Angelica MI, Correa-Gallego C, Jarnagin WR, Fong Y, Getrajdman GI, Allen P, and Kingham TP. Management of hepatocellular adenoma: Comparison of resection, embolization and observation. *HPB*. 2012.
295. **Gönen M**. Optimal bayesian enrichment: A view from the closet. *Biometrics*. 2012. 68(1): p. 215-216.
296. Martins FC, De S, Almendro V, **Gönen M**, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Gar JE, Fetteen K, Michor F, and Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. *Cancer Discovery*. 2012. 2(6): p. 503-511.
297. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, **Gönen M**, Kantarjian H, Levine RL, Abdel-Wahab O, and Verstovsek S. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. *Blood*. 2012. 119(19): p. 4480-4485.
298. **Gönen M**, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, and Paietta E. CD25 expression

- status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. *Blood*. 2012. 120(11): p. 2297-2306.
299. Maker AV, Butte JM, Oxenberg J, Kuk D, **Gönen M**, Fong Y, DeMatteo RP, D'Angelica MI, Allen PJ, and Jarnagin WR. Is port site resection necessary in the surgical management of gallbladder cancer? *Annals of Surgical Oncology*. 2012. 19(2): p. 409-417.
300. Ito K, Ito H, Kemeny NE, **Gönen M**, Allen PJ, Paty PB, Fong Y, DeMatteo RP, Blumgart LH, Jarnagin WR, and D'Angelica MI. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: Incidence, clinical features, and risk factors. *Annals of Surgical Oncology*. 2012. 19(5): p. 1609-1617.
301. Bickenbach KA, **Gönen M**, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, and Allen PJ. Downstaging in pancreatic cancer: A matched analysis of patients resected following systemic treatment of initially locally unresectable disease. *Annals of Surgical Oncology*. 2012. 19(5): p. 1663-1669.
302. Gaujoux S, Torres J, Olson S, Winston C, **Gönen M**, Brennan MF, Klimstra DS, D'Angelica M, DeMatteo R, Fong Y, House M, Jarnagin W, Kurtz RC, and Allen PJ. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. *Annals of Surgical Oncology*. 2012. 19(9): p. 2908-2916.
303. Gaujoux S, Al-Ahmadie H, Allen PJ, **Gönen M**, Shia J, D'Angelica M, DeMatteo R, Fong Y, Blumgart L, and Jarnagin WR. Resection of adrenocortical carcinoma liver metastasis: Is it justified? *Annals of Surgical Oncology*. 2012. 19(8): p. 2643-2651.
304. Dikken JL, Van De Velde CJH, **Gönen M**, Verheij M, Brennan MF, and Coit DG. The new american joint committee on cancer/international union against cancer staging system for adenocarcinoma of the stomach: Increased complexity without clear improvement in predictive accuracy. *Annals of Surgical Oncology*. 2012. 19(8): p. 2443-2451.
305. Sofocleous CT, Garg S, Petrovic LM, **Gönen M**, Petre EN, Klimstra DS, Solomon SB, Brown KT, Brody LA, Covey AM, DeMatteo RP, Schwartz L, and Kemeny NE. Ki-67 is a Prognostic Biomarker of Survival after Radiofrequency Ablation of Liver Malignancies. *Annals of Surgical Oncology*. 2012: p. 1-8.
306. Gaujoux S, **Gönen M**, Tang L, Klimstra D, Brennan MF, D'Angelica M, DeMatteo R, Allen PJ, Jarnagin W, and Fong Y. Synchronous Resection of Primary and Liver Metastases for Neuroendocrine Tumors. *Annals of Surgical Oncology*. 2012: p. 1-8.
307. Cardona K, Mastrodomenico P, D'Amico F, Shia J, **Gönen M**, Weiser MR, Paty PB, Kingham TP, Allen PJ, De Matteo RP, Fong Y, Jarnagin WR, and D'Angelica MI. Detailed Pathologic Characteristics of the Primary Colorectal Tumor Independently Predict Outcome after Hepatectomy for Metastases. *Annals of Surgical Oncology*. 2012: p. 1-7.
308. Weiss MJ, Ito H, Araujo RLC, Zabor EC, **Gönen M**, D'Angelica MI, Allen PJ, DeMatteo RP, Fong Y, Blumgart LH, and Jarnagin WR. Hepatic Pedicle Clamping During Hepatic Resection for Colorectal Liver Metastases: No Impact on Survival or Hepatic Recurrence. *Annals of Surgical Oncology*. 2012: p. 1-10.
309. Cardona K, Zhou Q, **Gönen M**, Shah MA, Strong VE, Brennan MF, and Coit DG. Role of Repeat Staging Laparoscopy in Locoregionally Advanced Gastric or Gastroesophageal Cancer after Neoadjuvant Therapy. *Annals of Surgical Oncology*. 2012: p. 1-7.

310. Bickenbach KA, Denton B, **Gönen M**, Brennan MF, Coit DG, and Strong VE. Impact of Obesity on Perioperative Complications and Long-term Survival of Patients with Gastric Cancer. *Annals of Surgical Oncology*. 2012: p. 1-8.
311. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, **Gönen M**, Jarnagin WR, Fong Y, D'Angelica MI, and DeMatteo RP. Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. *Annals of Surgical Oncology*. 2012: p. 1-10.
312. Dikken JL, Baser RE, **Gönen M**, Kattan MW, Shah MA, Verheij M, van de Velde CJH, Brennan MF, and Coit DG. Conditional Probability of Survival Nomogram for 1-, 2-, and 3-Year Survivors After an R0 Resection for Gastric Cancer. *Annals of Surgical Oncology*. 2012: p. 1-8.
313. Butte JM, Torres J, Veras EF, Matsuo K, **Gönen M**, D'Angelica MI, Waugh E, Meneses M, Inayama Y, Fong Y, DeMatteo RP, De La Fuente H, Endo I, Klimstra DS, and Jarnagin WR. Regional Differences in Gallbladder Cancer Pathogenesis: Insights from a Comparison of Cell Cycle-Regulatory, PI3K, and Pro-Angiogenic Protein Expression. *Annals of Surgical Oncology*. 2012: p. 1-12.
314. Haddad D, Chen CH, Carlin S, Silberhumer G, Chen NG, Zhang Q, Longo V, Carpenter SG, Mittra A, Carson J, Au J, **Gönen M**, Zanzonico PB, Szalay AA, and Fong Y. Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter. *PLoS ONE*. 2012. 7(8).
315. Lyall A, Capobianco J, Strauss HW, **Gönen M**, and Schöder H. Treadmill exercise inducing mild to moderate ischemia has no significant effect on skeletal muscle or cardiac 18F-FDG uptake and image quality on subsequent whole-body PET scan. *Journal of Nuclear Medicine*. 2012. 53(6): p. 917-921.
316. Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD, Roble G, Zanzonico PB, **Gönen M**, O'Donoghue J, Fischer A, and Humm JL. Image-guided PO 2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. *Journal of Nuclear Medicine*. 2012. 53(10): p. 1608-1615.
317. Tang M, Foo J, **Gönen M**, Guilhot J, Mahon F, and Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. *Haematologica*. 2012. 97(10): p. 1553-1561.
318. Wolf PS, Park JO, Bao F, Allen PJ, Dematteo RP, Fong Y, Jarnagin WR, Kingham TP, **Gönen M**, Kemeny N, Shia J, and D'Angelica MI. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: A single institution experience. *Journal of the American College of Surgeons*. 2013. 216(1): p. 41-49.
319. Ang C, O'Reilly EM, Carvajal RD, Capanu M, **Gönen M**, Doyle L, Ghossein R, Schwartz L, Jacobs G, Ma J, Schwartz GK, Abou-Alfa GK. A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. *Gastrointest Cancer Res*. 2012 Nov;5(6):185-9.
320. Sima CS, **Gönen M**. Optimal cutpoint estimation with censored data. *Journal of Statistical Theory and Practice*, 7: 345-359.

321. Trakarnsanga A, **Gönen M**, Shia J, Goodman KA, Nash GM, Temple LK, Guillem JG, Paty PB, Garcia-Aguilar J, Weiser MR. What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy? *Ann Surg Oncol*. 2013 Jan 18. [Epub ahead of print]
322. Burger IA, Vargas HA, Goldman DA, **Gönen M**, Kumar A, Zelenetz AD, Schöder H, Hricak H. The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging*. 2013 Feb 7. [Epub ahead of print]
323. Burger IA, Vargas HA, Donati OF, Andikyan V, Sala E, **Gönen M**, Goldman DA, Chi DS, Schöder H, Hricak H. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. *Gynecol Oncol*. 2013 Jan 29. doi:pil: S0090-8258(13)00027-9. 10.1016/j.ygyno.2013.01.017. [Epub ahead of print]
324. Bickenbach KA, **Gönen M**, Labow DM, Strong V, Heaney ML, Zelenetz AD, Coit DG. Indications for and efficacy of splenectomy for haematological disorders. *Br J Surg*. 2013 Feb 21. doi: 10.1002/bjs.9067. [Epub ahead of print]
325. Araujo RL, Gaujoux S, Huguet F, **Gönen M**, D'Angelica MI, Dematteo RP, Fong Y, Kingham TP, Jarnagin WR, Goodman KA, Allen PJ. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. *HPB (Oxford)*. 2013 Jan 10. doi: 10.1111/hpb.12033. [Epub ahead of print]
326. Karanicolas PJ, Graham D, **Gönen M**, Strong VE, Brennan MF, Coit DG. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. *Ann Surg*. 2013 Jun;257(6):1039-46. doi: 10.1097/SLA.0b013e31828c4a19. PubMed PMID: 23665970.
327. Lafemina J, Chou JF, **Gönen M**, Rocha FG, Correa-Gallego C, Kingham TP, Fong Y, D'Angelica MI, Jarnagin WR, Dematteo RP, Allen PJ. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? *J Gastrointest Surg*. 2013 Jun;17(6):1092-7. doi: 10.1007/s11605-012-2071-7. Epub 2013 Apr 16. PubMed PMID: 23588624.
328. Frankel TL, Fischer M, Grant F, Krone J, D'Angelica MI, Dematteo RP, Jarnagin WR, **Gönen M**. Selecting Patients for Acute Normovolemic Hemodilution during Hepatic Resection: A Prospective Randomized Evaluation of Nomogram-Based Allocation. *J Am Coll Surg*. 2013 May 31. doi:pil: S1072-7515(13)00270-6. 10.1016/j.jamcollsurg.2013.03.019. [Epub ahead of print] PubMed PMID: 23731968.
329. Lin Y, Chappell R, **Gönen M**. A systematic selection method for the development of cancer staging systems. *Stat Methods Med Res*. 2013 May 22. [Epub ahead of print] PubMed PMID: 23698866.
330. Karanicolas PJ, Jarnagin WR, **Gönen M**, Tuorto S, Allen PJ, Dematteo RP, D'Angelica MI, Fong Y. Long-term Outcomes Following Tumor Ablation for Treatment of Bilateral Colorectal Liver Metastases. *JAMA Surg*. 2013 May 8:1-4. doi: 10.1001/jamasurg.2013.1431. [Epub ahead of print] PubMed PMID: 23699996.
331. **Gönen M**. Mixtures of Receiver Operating Characteristic Curves. *Acad Radiol*. 2013 May 2. doi:pil: S1076-6332(13)00112-8. 10.1016/j.acra.2013.03.003. [Epub ahead of print] PubMed PMID: 23643788.

332. Lu Y, Jansen JF, Stambuk HE, Gupta G, Lee N, **Gönen M**, Moreira A, Mazaheri Y, Patel SG, Deasy JO, Shah JP, Shukla-Dave A. Comparing primary tumors and metastatic nodes in head and neck cancer using intravoxel incoherent motion imaging: a preliminary experience. *J Comput Assist Tomogr.* 2013 May-Jun;37(3):346-52. doi: 10.1097/RCT.0b013e318282d935. PubMed PMID: 23674004; PubMed Central PMCID: PMC3655331.
333. Hakimi AA, Ostrovnaya I, Reva BA, Schultz N, Chen YB, **Gönen M**, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ. Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: a Report by MSKCC and the KIRC TCGA Research Network. *Clin Cancer Res.* 2013 Apr 25. [Epub ahead of print] PubMed PMID: 23620406.
334. Correa-Gallego C, **Gönen M**, Fischer M, Grant F, Kemeny NE, Arslan-Carlon V, Kingham TP, Dematteo RP, Fong Y, Allen PJ, D'Angelica MI, Jarnagin WR. Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. *Ann Surg Oncol.* 2013 Apr 23. [Epub ahead of print] PubMed PMID: 23608971.
335. Araujo RL, Karkar AM, Allen PJ, **Gönen M**, Chou JF, Brennan MF, Blumgart LH, D'Angelica MI, Dematteo RP, Coit DG, Fong Y, Jarnagin WR. Timing of elective surgery as a perioperative outcome variable: analysis of pancreaticoduodenectomy. *HPB (Oxford).* 2013 Apr 18. doi: 10.1111/hpb.12107. [Epub ahead of print] PubMed PMID: 23600897.
336. Erinjeri JP, Thomas CT, Samoilia A, Fleisher M, **Gönen M**, Sofocleous CT, Thornton RH, Siegelbaum RH, Covey AM, Brody LA, Alago W Jr, Maybody M, Brown KT, Getrajdman GI, Solomon SB. Image-guided Thermal Ablation of Tumors Increases the Plasma Level of Interleukin-6 and Interleukin-10. *J Vasc Interv Radiol.* 2013 Apr 9. doi:p11: S1051-0443(13)00621-0. 10.1016/j.jvir.2013.02.015. [Epub ahead of print] PubMed PMID: 23582441.
337. Cavell LK, Allen PJ, Vinoya C, Eaton AA, **Gönen M**, Gerdes H, Mendelsohn RB, D'Angelica MI, Kingham TP, Fong Y, Dematteo R, Jarnagin WR, Kurtz RC, Schattner MA. Biliary Self-Expandable Metal Stents Do Not Adversely Affect Pancreaticoduodenectomy. *Am J Gastroenterol.* 2013 Apr 2. doi: 10.1038/ajg.2013.93. [Epub ahead of print] PubMed PMID: 23545711.
338. Bickenbach KA, **Gönen M**, Strong V, Brennan MF, Coit DG. Association of Positive Transection Margins with Gastric Cancer Survival and Local Recurrence. *Ann Surg Oncol.* 2013 Mar 28. [Epub ahead of print] PubMed PMID: 23536054.
339. Crago AM, Denton B, Salas S, Dufresne A, Mezhir JJ, Hameed M, **Gönen M**, Singer S, Brennan MF. A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis. *Ann Surg.* 2013 Mar 25. [Epub ahead of print] PubMed PMID: 23532110.
340. **Gönen M**. Visualizing Longitudinal Data With Dropouts. *The American Statistician*, 2013, 67, 97-103.
341. Frankel TL, Fischer M, Grant F, Krone J, D'Angelica MI, Dematteo RP, Jarnagin WR, **Gönen M**. Selecting Patients for Acute Normovolemic Hemodilution during Hepatic Resection: A Prospective Randomized Evaluation of Nomogram-Based Allocation. *J Am Coll Surg.* 2013 May 31. doi:p11: S1072-7515(13)00270-6. 10.1016/j.jamcollsurg.2013.03.019. [Epub ahead of print] PMID: 23731968.

342. Ammori JB, Kemeny NE, Fong Y, Cercek A, Dematteo RP, Allen PJ, Kingham TP, **Gönen M.**, Paty PB, Jarnagin WR, D'Angelica MI. Conversion to Complete Resection and/or Ablation Using Hepatic Artery Infusional Chemotherapy in Patients with Unresectable Liver Metastases from Colorectal Cancer: A Decade of Experience at a Single Institution. *Ann Surg Oncol*. 2013 Sep;20(9):2901-7. doi: 10.1245/s10434-013-3009-3. Epub 2013 Jun 15. PMID: 23771246.
343. Tan MC, Butte JM, **Gönen M.**, Kemeny N, Fong Y, Allen PJ, Kingham TP, Dematteo RP, Jarnagin WR, D'Angelica MI. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. *HPB (Oxford)*. 2013 Jun 19. doi: 10.1111/hpb.12136. [Epub ahead of print] PMID: 23782400.
344. Capanu M, **Gönen M.**, Begg CB. An assessment of estimation methods for generalized linear mixed models with binary outcomes. *Stat Med*. 2013 Jul 9. doi: 10.1002/sim.5866. [Epub ahead of print] PMID: 23839712.
345. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, **Gönen M.**, Montorsi F, Shariat SF, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol*. 2013 Jul 2. doi:pii: S0302-2838(13)00656-8. 10.1016/j.eururo.2013.06.041. [Epub ahead of print] PMID: 23850255.
346. Sofocleous CT, Garg SK, Cohen P, Petre EN, **Gönen M.**, Erinjeri JP, Downey RJ, Travis WD, Solomon SB. Ki 67 is an Independent Predictive Biomarker of Cancer Specific and Local Recurrence-Free Survival After Lung Tumor Ablation. *Ann Surg Oncol*. 2013 Jul 30. [Epub ahead of print]. PMID: 23897007.
347. Begg CB, **Gönen M.**, Seshan VE. Testing the incremental predictive accuracy of new markers. *Clin Trials*. 2013 Jul 23. [Epub ahead of print] PMID: 23881367.
348. Zabor EC, **Gönen M.**, Chapman PB, Panageas KS. Dynamic prognostication using conditional survival estimates. *Cancer*. 2013 Aug 1. doi: 10.1002/cncr.28273. [Epub ahead of print] PMID: 23913639.
349. Araujo R, **Gönen M.**, Allen P, Blumgart L, Dematteo R, Fong Y, Kemeny N, Jarnagin W, D'Angelica M. Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer. *Ann Surg Oncol*. 2013 Jul 30. [Epub ahead of print] PMID: 23897009 [PubMed - as supplied by publisher]
350. Silberhumer GR, Rahmel A, Karam V, **Gönen M.**, Gyoeri G, Kern B, Adam R, Muehlbacher F, Rogiers X, Burroughs AK, Berlakovich GA. The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. *Transpl Int*. 2013 Jul 16. doi: 10.1111/tri.12156. [Epub ahead of print] PMID: 23931659.
351. Gollub MJ, Cao K, Gultekin DH, Kuk D, **Gönen M.**, Sohn M, Schwartz LH, Weiser MR, Temple LK, Nash GM, Guillem JG, Wang M, Garcia-Aguilar J, Goodman K, Paty PB. Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer. *Eur Radiol*. 2013 Aug 27. [Epub ahead of print] PMID: 23979104.

352. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, **Gönen M.**, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. *Nat Biotechnol.* 2013 Aug 11. doi: 10.1038/nbt.2678. [Epub ahead of print] PMID: 23934177.
353. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, **Gönen M.**, Fleisher M, Larson SM, Sawyers CL, Scher HI. Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. *J Clin Oncol.* 2013 Sep 3. [Epub ahead of print] PMID: 24002508.
354. Correa-Gallego C, Do R, Lafemina J, **Gönen M**, D'Angelica MI, Dematteo RP, Fong Y, Kingham TP, Brennan MF, Jarnagin WR, Allen PJ. Predicting Dysplasia and Invasive Carcinoma in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Development of a Preoperative Nomogram. *Ann Surg Oncol.* 2013 Sep 18. [Epub ahead of print] PMID: 24046103.
355. Senses KM, **Gönen M**, Barutcu AR, Kalaylioglu Z, Isbilen M, Konu O, Chen YT, Altorki NK, Gure AO. Cancer-testis gene expression is associated with the methylenetetrahydrofolate reductase 677 C>T polymorphism in non-small cell lung carcinoma. *BMC Med Genet.* 2013 Sep 24;14(1):97. [Epub ahead of print] PMID: 24063603.
356. Pugalenthi A, Bradley C, **Gönen M**, Do KG, Strong V, Jarnagin W, Coit D, Kingham TP. Splenectomy to treat splenic lesions: An analysis of 148 cases at a cancer center. *J Surg Oncol.* 2013 Sep 16. doi: 10.1002/jso.23433. [Epub ahead of print] PMID: 24105804.
357. Gholami S, Chen CH, Lou E, Belin LJ, Fujisawa S, Longo VA, Chen NG, **Gönen M**, Zanzonico PB, Szalay AA, Fong Y. Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer. *FASEB J.* 2013 Nov 1. [Epub ahead of print] PMID: 24186964.
358. Bommelje CC, Weeda VB, Huang G, Shah K, Bains S, Buss E, Shaha M, **Gönen M**, Ghoissein R, Ramanatham Y, Singh B. Oncogenic function of SCCRO5/DCUN1D5 Requires its Neddylation E3 Activity and Nuclear Localization. *Clin Cancer Res.* 2013 Nov 5. [Epub ahead of print] PMID: 24192928.
359. Ulaner GA, Lilienstein J, **Gönen M**, Maragulia J, Moskowitz CH, Zelenetz AD. False-Positive [18F]Fluorodeoxyglucose-Avid Lymph Nodes on Positron Emission Tomography-Computed Tomography After Allogeneic but Not Autologous Stem-Cell Transplantation in Patients With Lymphoma. *J Clin Oncol.* 2014 Jan 1;32(1):51-6. doi: 10.1200/JCO.2013.50.8044. Epub 2013 Nov 18. PMID: 24248697.
360. Goldman DA, **Gönen M**, Hricak H, Kang SK, Touijer KA. Correction of data reporting errors. *Radiology.* 2013 Dec;269(3):949-50. doi: 10.1148/radiol.13134035. No abstract available. PMID: 24261507.
361. Sofocleous CT, Petre EN, **Gönen M**, Reidy-Lagunes D, Ip IK, Alago W, Covey AM, Erinjeri JP, Brody LA, Maybody M, Thornton RH, Solomon SB, Getrajdman GI, Brown KT. Factors Affecting Periprocedural Morbidity and Mortality and Long-term Patient Survival after Arterial Embolization of Hepatic Neuroendocrine Metastases. *J Vasc Interv Radiol.* 2014 Jan;25(1):22-30. doi: 10.1016/j.jvir.2013.09.013. PMID: 24365504.

362. Bamboat ZM, Tang LH, Vinuela E, Kuk D, **Gönen M**, Shah MA, Brennan MF, Coit DG, Strong VE. Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma. *Ann Surg Oncol*. 2014 Jan 7. [Epub ahead of print] PMID: 24394986.
363. Dikken JL, Coit DG, Baser RE, **Gönen M**, Goodman KA, Brennan MF, Jansen EP, Boot H, van de Velde CJ, Cats A, Verheij M. Performance of a Nomogram Predicting Disease-Specific Survival After an R0 Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy. *Int J Radiat Oncol Biol Phys*. 2014 Jan 7. pii: S0360-3016(13)03538-4. doi: 10.1016/j.ijrobp.2013.11.213. [Epub ahead of print] PMID: 24411620.
364. Schrag D, Weiser MR, Goodman KA, **Gönen M**, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. *J Clin Oncol*. 2014 Jan 13. [Epub ahead of print] PMID: 24419115.
365. Almendro V, Kim H, Cheng YK, **Gönen M**, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K. Genetic and phenotypic diversity in breast tumor metastases. *Cancer Res*. 2014 Jan 21. [Epub ahead of print]. PMID: 24448237.
366. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, **Gönen M**, Michor F, Polyak K. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. *Cell Rep*. 2014 Feb 13;6(3):514-27. doi: 10.1016/j.celrep.2013.12.041. Epub 2014 Jan 23. PMID: 24462293.
367. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, **Gönen M**, Larson SM, Morris MJ, Scher HI, Hricak H. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. *Radiology*. 2014 Apr;271(1):220-9. doi: 10.1148/radiol.13130625. Epub 2013 Nov 18 PMID: 24475817.
368. Hakimi AA, Mano R, Ciriello G, **Gönen M**, Mikkilineni N, Sfakianos JP, Kim PH, Motzer RJ, Russo P, Reuter VE, Hsieh JJ, Ostrovskaya I. Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. *J Urol*. 2014 Feb 8. pii: S0022-5347(14)00122-0. doi: 10.1016/j.juro.2014.01.088. [Epub ahead of print] PMID: 24518768.
369. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, **Gönen M**, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralto S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226. PMID: 24553386.

370. Shim JH, Song KY, Jeon HM, Park CH, Jacks LM, **Gönen M**, Shah MA, Brennan MF, Coit DG, Strong VE. Is Gastric Cancer Different in Korea and the United States? Impact of Tumor Location on Prognosis. *Ann Surg Oncol*. 2014 Mar 6. [Epub ahead of print] PMID: 24599411.
371. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, **Gönen M**, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80. doi: 10.1200/JCO.2013.53.8009. Epub 2014 Mar 17. No abstract available. PMID: 24638016.
372. Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, Gao J, Schultz N, **Gönen M**, Soslow RA, Berger MF, Levine DA. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. *Nat Genet*. 2014 May;46(5):424-6. doi: 10.1038/ng.2922. Epub 2014 Mar 23. PMID: 24658004.
373. Konstantinidis IT, Do RK, Gultekin DH, **Gönen M**, Schwartz LH, Fong Y, Allen PJ, D'Angelica MI, Dematteo RP, Klimstra DS, Kemeny NE, Jarnagin WR. Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials. *Ann Surg Oncol*. 2014 Mar 25. [Epub ahead of print] PMID: 24664624.
374. Burger IA, Vargas HA, Apte A, Beattie BJ, Humm JL, **Gönen M**, Larson SM, Ross Schmidtlein C. PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. *Nucl Med Biol*. 2014 May-Jun;41(5):410-8. doi: 10.1016/j.nucmedbio.2014.02.006. Epub 2014 Feb 28. PMID: 24666719.
375. Terezakis SA, Schöder H, Kowalski A, McCann P, Lim R, Turlakov A, **Gönen M**, Barker C, Goenka A, Lovie S, Yahalom J. A Prospective Study of (18)FDG-PET With CT Coregistration for Radiation Treatment Planning of Lymphomas and Other Hematologic Malignancies. *Int J Radiat Oncol Biol Phys*. 2014 Jun 1;89(2):376-83. doi: 10.1016/j.ijrobp.2014.02.006. Epub 2014 Apr 11. PMID: 24726287.
376. Allen PJ, **Gönen M**, Brennan MF, Bucknor AA, Robinson LM, Pappas MM, Carlucci KE, D'Angelica MI, DeMatteo RP, Kingham TP, Fong Y, Jarnagin WR. Pasireotide for postoperative pancreatic fistula. *N Engl J Med*. 2014 May 22;370(21):2014-22. doi: 10.1056/NEJMoa1313688. PMID: 24849084.
377. Simpson AL, Geller DA, Hemming AW, Jarnagin WR, Clements LW, D'Angelica MI, Dumpuri P, **Gönen M**, Zendejas I, Miga MI, Stefansic JD. Liver Planning Software Accurately Predicts Postoperative Liver Volume and Measures Early Regeneration. *J Am Coll Surg*. 2014 Mar 27. pii: S1072-7515(14)00282-8. doi: 10.1016/j.jamcollsurg.2014.02.027. [Epub ahead of print] PMID: 24862883.
378. Huang EP, Wang XF, Roy Choudhury K, McShane LM, **Gönen M**, Ye J, Buckler AJ, Kinahan PE, Reeves AP, Jackson EF, Guimaraes AR, Zahlmann G; Meta-Analysis Working Group. Meta-analysis of the technical performance of an imaging procedure: Guidelines and statistical methodology. *Stat Methods Med Res*. 2014 May 28. pii: 0962280214537394. [Epub ahead of print] PMID: 24872353.

379. Rich BS, Honeyman JN, Darcy DG, Smith PT, Williams AR, Lim II, Johnson LK, **Gönen M**, Simon JS, LaQuaglia MP, Simon SM. Endogenous antibodies for tumor detection. *Sci Rep*. 2014 May 30;4:5088. doi: 10.1038/srep05088. PMID: 24875800.
380. Correa-Gallego C, Fong Y, **Gönen M**, D'Angelica MI, Allen PJ, DeMatteo RP, Jarnagin WR, Kingham TP. A Retrospective Comparison of Microwave Ablation vs. Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. *Ann Surg Oncol*. 2014 Jun 3. [Epub ahead of print] PMID: 24889486.
381. Podlaha O, De S, **Gönen M**, Michor F. Histone modifications are associated with transcript isoform diversity in normal and cancer cells. *PLoS Comput Biol*. 2014 Jun 5;10(6):e1003611. doi: 10.1371/journal.pcbi.1003611. eCollection 2014 Jun. PMID: 24901363.
382. Raunig DL, McShane LM, Pennello G, Gatsonis C, Carson PL, Voyvodic JT, Wahl RL, Kurland BF, Schwarz AJ, **Gönen M**, Zahlmann G, Kondratovich M, O'Donnell K, Petrick N, Cole PE, Garra B, Sullivan DC; QIBA Technical Performance Working Group. Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. *Stat Methods Med Res*. 2014 Jun 11. pii: 0962280214537344. [Epub ahead of print] PMID: 24919831.
383. Saluja S, Alatisse OI, Adewale A, Misholy J, Chou J, **Gönen M**, Weiser M, Kingham TP. A comparison of colorectal cancer in Nigerian and North American patients: Is the cancer biology different? *Surgery*. 2014 Aug;156(2):305-10. doi: 10.1016/j.surg.2014.03.036. Epub 2014 Jun 19. PMID: 24953266.
384. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, **Gönen M**, Briganti A, Shariat SF. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. *Br J Cancer*. 2014 Jul 15;111(2):213-9. doi: 10.1038/bjc.2014.311. Epub 2014 Jul PMID: 25003663.
385. Lee SY, Konstantinidis IT, Eaton AA, **Gönen M**, Kingham TP, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR. Predicting recurrence patterns after resection of hepatocellular cancer. *HPB (Oxford)*. 2014 Jul 16. doi: 10.1111/hpb.12311. [Epub ahead of print] PMID: 25041404.
386. Sadot E, Brennan MF, Lee SY, Allen PJ, **Gönen M**, Groeger JS, Peter Kingham T, D'Angelica MI, DeMatteo RP, Jarnagin WR, Fong Y. Readmission After Pancreatic Resection: Causes and Causality Pattern. *Ann Surg Oncol*. 2014 Jul 22. [Epub ahead of print] PMID: 25047467.
387. Liu W, Shia J, **Gönen M**, Lowery MA, O'Reilly EM, Klimstra DS. DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas: Frequency and Clinical Significance. *Pancreas*. 2014 Jul 23. [Epub ahead of print] PMID: 25058881.
388. Butte JM, Kingham TP, **Gönen M**, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR. Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. *J Am Coll Surg*. 2014 Sep;219(3):416-29. doi: 10.1016/j.jamcollsurg.2014.01.069. Epub 2014 May 16. PMID: 25087941.

389. Olshen A, Tang M, Cortes J, **Gönen M**, Hughes T, Branford S, Quintás-Cardama A, Michor F. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. *Haematologica*. 2014 Sep 12. pii: haematol.2013.085977. [Epub ahead of print] PMID: 25216683.
390. Trakarnsanga A, **Gönen M**, Shia J, Nash GM, Temple LK, Guillem JG, Paty PB, Goodman KA, Wu A, Gollub M, Segal N, Saltz L, Garcia-Aguilar J, Weiser MR. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. *J Natl Cancer Inst*. 2014 Sep 22;106(10). pii: dju248. doi: 10.1093/jnci/dju248. PMID: 25249540.
391. Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, **Gönen M**, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. (89)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. *Eur J Nucl Med Mol Imaging*. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21. PMID: 25143071.
392. Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, **Gönen M**, Weber WA, Ulaner GA. Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years. *J Nucl Med*. 2014 Oct;55(10):1578-83. doi: 10.2967/jnumed.114.143297. Epub 2014 Sep 11. PMID: 25214641.
393. Leung U, Simpson AL, Araujo RL, **Gönen M**, McAuliffe C, Miga MI, Parada EP, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Fong Y, Jarnagin WR. Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. *J Am Coll Surg*. 2014 Oct;219(4):620-30. doi: 10.1016/j.jamcollsurg.2014.04.022. Epub 2014 Jun 25. PMID: 25158914.
394. Groot Koerkamp B, Wiggers JK, Allen PJ, Busch OR, D'Angelica MI, DeMatteo RP, Fong Y, **Gönen M**, Gouma DJ, Kingham TP, van Gulik TM, Jarnagin WR. American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. *HPB (Oxford)*. 2014 Sep 29. doi: 10.1111/hpb.12320. [Epub ahead of print] PMID: 25267346.
395. Ye J, Zhou Y, Weiser MR **Gönen M**, Zhang L, Samdani T, Bacares R, DeLair D, Ivelja S, Vakiani E, Klimstra DS, Soslow RA, Shia J. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. *Hum Pathol*. 2014 Sep 2. [Epub ahead of print] PMID: 25311944.
396. Sadot E, Yahalom J, Do RK, Teruya-Feldstein J, Allen PJ, **Gönen M**, D'Angelica MI, Peter Kingham T, Jarnagin WR, DeMatteo RP. Clinical Features and Outcome of Primary Pancreatic Lymphoma. *Ann Surg Oncol*. 2014 Oct 24. [Epub ahead of print] PMID: 25341750.
397. Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, **Gönen M**, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS. Clinical translation of an ultras-small inorganic optical-PET imaging nanoparticle probe. *Sci Transl Med*. 2014 Oct 29;6(260):260ra149. Epub 2014 Oct 29. PMID: 25355699.

398. Sadot E, Basturk O, Klimstra DS, **Gönen M**, Anna L, Do RK, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ. Tumor-Associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-Risk Disease. *Ann Surg*. 2015 Jan 5. [Epub ahead of print] PMID: 25563865.
399. Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA Iii, Carducci MA, Dicker AP, **Gönen M**, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM. American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. *J Clin Oncol*. 2014 Dec 15. [Epub ahead of print] PMID: 25512456.
400. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, **Gönen M**, Larson SM, Morris MJ, Scher HI, Hricak H. Response. *Radiology*. 2015 Feb;274(2):625. PubMed PMID: 25785291.
401. Babur Ö, **Gönen M**, Aksoy BA, Schultz N, Ciriello G, Sander C, Demir E. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. *Genome Biol*. 2015 Feb 26;16:45. doi: 10.1186/s13059-015-0612-6. PubMed PMID: 25887147; PubMed Central PMCID: PMC4381444.
402. Park SM, **Gönen M**, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. *J Clin Invest*. 2015 Mar 2;125(3):1286-98. doi: 10.1172/JCI78440. Epub 2015 Feb 9. PubMed PMID: 25664853; PubMed Central PMCID: PMC4362230.
403. Simpson AL, Leal JN, Pugalenti A, Allen PJ, DeMatteo RP, Fong Y, **Gönen M**, Jarnagin WR, Kingham TP, Miga MI, Shia J, Weiser MR, D'Angelica MI. Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer. *J Am Coll Surg*. 2015 Mar;220(3):271-80. doi: 10.1016/j.jamcollsurg.2014.12.008. Epub 2014 Dec 13. PubMed PMID: 25617913; PubMed Central PMCID: PMC4411084.
404. Kingham TP, Correa-Gallego C, D'Angelica MI, **Gönen M**, DeMatteo RP, Fong Y, Allen PJ, Blumgart LH, Jarnagin WR. Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4,152 resections for malignancy. *J Am Coll Surg*. 2015 Apr;220(4):471-9. doi: 10.1016/j.jamcollsurg.2014.12.026. Epub 2014 Dec 27. PubMed PMID: 25667141; PubMed Central PMCID: PMC4529114.
405. Balachandran VP, **Gönen M**, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. *Lancet Oncol*. 2015 Apr;16(4):e173-80. doi: 10.1016/S1470-2045(14)71116-7. Review. PubMed PMID: 25846097; PubMed Central PMCID: PMC4465353.
406. Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, **Gönen M**, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. *EJNMMI Res*. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015. PubMed PMID: 25984435; PubMed Central PMCID: PMC4425739.

407. Dashevsky BZ, Goldman DA, Parsons M, **Gönen M**, Corben AD, Jochelson MS, Hudis CA, Morrow M, Ulaner GA. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. *Eur J Nucl Med Mol Imaging*. 2015 May 14. [Epub ahead of print] PubMed PMID: 25971426.
408. Brown AM, Nagala S, McLean MA, Lu Y, Scoffings D, Apte A, **Gönen M**, Stambuk HE, Shaha AR, Tuttle RM, Deasy JO, Priest AN, Jani P, Shukla-Dave A, Griffiths J. Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. *Magn Reson Med*. 2015 May 20. doi: 10.1002/mrm.25743. [Epub ahead of print] PubMed PMID: 25995019.
409. Lu Y, Hatzoglou V, Banerjee S, Stambuk HE, **Gönen M**, Shankaranarayanan A, Mazaheri Y, Deasy JO, Shaha AR, Tuttle RM, Shukla-Dave A. Repeatability Investigation of Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging on Thyroid Glands. *J Comput Assist Tomogr*. 2015 May-Jun;39(3):334-9. doi: 10.1097/RCT.0000000000000227. PubMed PMID: 25700226; PubMed Central PMCID: PMC4433417.
410. Ulaner GA, Goldman DA, Sauter CS, Migliacci J, Lilienstein J, **Gönen M**, Schöder H, Moskowitz CH, Zelenetz AD. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. *Radiology*. 2015 Jun 2:142556. [Epub ahead of print] PubMed PMID: 26035588.
411. Sadot E, Doussot A, O'Reilly EM, Lowery MA, Goodman KA, Do RK, Tang LH, **Gönen M**, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. *Ann Surg Oncol*. 2015 Jun 12. [Epub ahead of print] PubMed PMID: 26065868.
412. Lu Y, Moreira AL, Hatzoglou V, Stambuk HE, **Gönen M**, Mazaheri Y, Deasy JO, Shaha AR, Tuttle RM, Shukla-Dave A. Using diffusion-weighted MRI to predict aggressive histological features in papillary thyroid carcinoma: a novel tool for pre-operative risk stratification in thyroid cancer. *Thyroid*. 2015 Jun;25(6):672-80. doi: 10.1089/thy.2014.0419. Epub 2015 Apr 21. PubMed PMID: 25809949; PubMed Central PMCID: PMC4490628.
413. Silberhumer GR, Paty PB, Temple LK, Araujo RL, Denton B, **Gönen M**, Nash GM, Allen PJ, DeMatteo RP, Guillem J, Weiser MR, D'Angelica MI, Jarnagin WR, Wong DW, Fong Y. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. *Am J Surg*. 2015 Jun;209(6):935-42. doi: 10.1016/j.amjsurg.2014.09.024. Epub 2014 Dec 13. PubMed PMID: 25601556.
414. Sofocleous CT, Violari EG, Sotirchos VS, Shady W, **Gönen M**, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. *Clin Colorectal Cancer*. 2015 Jun 27. pii: S1533-0028(15)00075-4. doi: 10.1016/j.clcc.2015.06.003. [Epub ahead of print] PubMed PMID: 26277696.
415. Strong VE, Wu AW, Selby LV, **Gönen M**, Hsu M, Song KY, Park CH, Coit DG, Ji JF, Brennan MF. Differences in gastric cancer survival between the U.S. and China. *J Surg Oncol*. 2015 Jul;112(1):31-7. doi: 10.1002/jso.23940. Epub 2015 Jul 14. PubMed PMID: 26175203.

416. Sadot E, Simpson AL, Do RK, **Gönen M**, Shia J, Allen PJ, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR. Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. *PLoS One*. 2015 Jul 24;10(7):e0132953. doi: 10.1371/journal.pone.0132953. eCollection 2015. PubMed PMID: 26207380; PubMed Central PMCID: PMC4514866.
417. Kong M, Drill EN, Morris L, West L, Klimstra D, **Gönen M**, Ghossein R, Katabi N. Prognostic factors in myoepithelial carcinoma of salivary glands: a clinicopathologic study of 48 cases. *Am J Surg Pathol*. 2015 Jul;39(7):931-8. doi: 10.1097/PAS.0000000000000452. PubMed PMID: 25970687.
418. Iasonos A, **Gönen M**, Bosl GJ. Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed? *J Clin Oncol*. 2015 Jul 1;33(19):2221-5. doi: 10.1200/JCO.2014.59.8466. Epub 2015 May 4. PubMed PMID: 25940721.
419. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylgeril V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, **Gönen M**, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne J, Lewis JS, Reuter V, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. *Clin Cancer Res*. 2015 Jul 14. pii: clincanres.0552.2015. [Epub ahead of print] PubMed PMID: 26175541.
420. Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, **Gönen M**, Shah JP. Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. *Ann Surg Oncol*. 2015 Jul 28. [Epub ahead of print] PubMed PMID: 26215199.
421. Correa-Gallego C, Tan KS, Arslan-Carlson V, **Gönen M**, Denis SC, Langdon-Embry L, Grant F, Kingham TP, DeMatteo RP, Allen PJ, D'Angelica MI, Jarnagin WR, Fischer M. Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial. *J Am Coll Surg*. 2015 Aug;221(2):591-601. doi: 10.1016/j.jamcollsurg.2015.03.050. Epub 2015 Apr 7. PubMed PMID: 26206652.
422. Doussot A, Groot-Koerkamp B, Wiggers JK, Chou J, **Gönen M**, DeMatteo RP, Allen PJ, Kingham TP, D'Angelica MI, Jarnagin WR. Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. *J Am Coll Surg*. 2015 Aug;221(2):452-61. doi: 10.1016/j.jamcollsurg.2015.04.009. Epub 2015 Apr 24. PubMed PMID: 26206643.
423. Leal JN, **Gönen M**, Covey AM, Erinjeri JP, Getrajdman G, Sofocleous CT, D'Angelica M, DeMatteo RP, Abou-Alfa GK, Jarnagin WR, Fong Y, Brown KT. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. *J Vasc Interv Radiol*. 2015 Aug;26(8):1112-21. doi: 10.1016/j.jvir.2015.04.006. Epub 2015 May 30. PubMed PMID: 26038273; PubMed Central PMCID: PMC4535717.

424. Butte JM, **Gönen M**, Allen PJ, Peter Kingham T, Sofocleous CT, DeMatteo RP, Fong Y, Kemeny NE, Jarnagin WR, D'Angelica MI. Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. *Ann Surg Oncol*. 2015 Aug;22(8):2761-71. doi: 10.1245/s10434-015-4370-1. Epub 2015 Jan 9. PubMed PMID: 25572686.
425. Copur MS, Ramaekers R, **Gönen M**, Gulzow M, Hadenfeldt R, Fuller C, Scott J, Einspahr S, Benzel H, Mickey M, Norvell M, Clark D, Gauchan D, Kurbegov D. Impact of the National Cancer Institute Community Cancer Centers Program on Clinical Trial and Related Activities at a Community Cancer Center in Rural Nebraska. *J Oncol Pract*. 2015 Aug 11. pii: JOP.2015.005736. [Epub ahead of print] PubMed PMID: 26265173.
426. Shady W, Petre EN, **Gönen M**, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D'Angelica MI, Jarnagin WR, Solomon SB, Kemeny NE, Sofocleous CT. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes-A 10-year Experience at a Single Center. *Radiology*. 2015 Aug 12:142489. [Epub ahead of print] PubMed PMID: 26267832.
427. Parsons M, Goldman D, Dashevsky B, Riedl CC, **Gönen M**, Osborne J, Jochelson M, Hudis C, Morrow M, Ulaner G. Value of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Breast Cancer (ILC) as Compared with Invasive Ductal Breast Cancer (IDC). *J Nucl Med*. 2015 Aug 20. pii: jnumed.115.161455. [Epub ahead of print] PubMed PMID: 26294295.
428. Sadot E, Groot Koerkamp B, Leal JN, Shia J, **Gönen M**, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, D'Angelica MI. Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer: Surgical Technique or Biologic Surrogate? *Ann Surg*. 2015 Sep;262(3):476-85. doi: 10.1097/SLA.0000000000001427. PubMed PMID: 26258316; PubMed Central PMCID: PMC4533113.
429. Araujo RL, **Gönen M**, Herman P. Chemotherapy for Patients with Colorectal Liver Metastases Who Underwent Curative Resection Improves Long-Term Outcomes: Systematic Review and Meta-analysis. *Ann Surg Oncol*. 2015 Sep;22(9):3070-8. doi: 10.1245/s10434-014-4354-6. Epub 2015 Jan 14. PubMed PMID: 25586244.
430. Araujo RL, **Gönen M**, Allen P, DeMatteo R, Kingham P, Jarnagin W, D'Angelica M, Fong Y. Positive Postoperative CEA is a Strong Predictor of Recurrence for Patients After Resection for Colorectal Liver Metastases. *Ann Surg Oncol*. 2015 Sep;22(9):3087-93. doi: 10.1245/s10434-014-4358-2. Epub 2015 Jan 13. PubMed PMID: 25582745; PubMed Central PMCID: PMC4526451.
431. Groot Koerkamp B, Wiggers JK, **Gönen M**, Doussot A, Allen PJ, Besselink MG, Blumgart LH, Busch OR, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, van Gulik TM, Jarnagin WR. Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. *Ann Oncol*. 2015 Sep;26(9):1930-5. doi: 10.1093/annonc/mdv279. Epub 2015 Jun 30. Review. PubMed PMID: 26133967.

432. Copur MS, Ramaekers R, **Gönen M**, Gulzow M, Hadenfeldt R, Fuller C, Scott J, Einspahr S, Benzel H, Mickey M, Norvell M, Clark D, Gauchan D, Kurbegov D, Copur MS, Ramaekers R, Gönen M, Gulzow M, Hadenfeldt R, Fuller C, Scott J, Einspahr S, et al. Impact of the National Cancer Institute Community Cancer Centers Program on Clinical Trial and Related Activities at a Community Cancer Center in Rural Nebraska. *J Oncol Pract*. 2016 Jan;12(1):67-8, e44-51. doi: 10.1200/JOP.2015.005736. Epub 2015 Aug 11. PubMed [citation] PMID: 26265173, PMCID: PMC4976454
433. Shady W, Petre EN, **Gönen M**, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D'Angelica MI, Jarnagin WR, Solomon SB, Kemeny NE, Sofocleous CT. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. *Radiology*. 2016 Feb;278(2):601-11. doi: 10.1148/radiol.2015142489. Epub 2015 Aug 12. PubMed [citation] PMID: 26267832, PMCID: PMC4734163
434. Sofocleous CT, Violari EG, Sotirchos VS, Shady W, **Gönen M**, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. *Clin Colorectal Cancer*. 2015 Dec;14(4):296-305. doi: 10.1016/j.clcc.2015.06.003. Epub 2015 Jun 27. PubMed [citation] PMID: 26277696
435. Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. *J Nucl Med*. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20. PubMed [citation] PMID: 26294295, PMCID: PMC4869690
436. Lee SY, Sadot E, Chou JF, Gönen M, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. Central hepatectomy versus extended hepatectomy for liver malignancy: a matched cohort comparison. *HPB (Oxford)*. 2015 Nov;17(11):1025-32. doi: 10.1111/hpb.12507. Epub 2015 Sep 10. PubMed [citation] PMID: 26353922, PMCID: PMC4605342
437. Wiggers JK, Groot Koerkamp B, Coelen RJ, Rauws EA, Schattner MA, Nio CY, Brown KT, **Gönen M**, van Dieren S, van Lienden KP, Allen PJ, Besselink MG, Busch OR, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM. Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage. *Endoscopy*. 2015 Dec;47(12):1124-31. doi: 10.1055/s-0034-1392559. Epub 2015 Sep 18. PubMed [citation] PMID: 26382308, PMCID: PMC4745253

438. Sala E, Micco M, Burger IA, Yakar D, Kollmeier MA, Goldman DA, **Gönen M**, Park KJ, Abu-Rustum NR, Hricak H, Vargas HA. Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer. *Int J Gynecol Cancer*. 2015 Oct;25(8):1461-7. doi: 10.1097/IGC.0000000000000519. PubMed [citation] PMID: 26397068, PMCID: PMC4998040
439. Sadot E, Lee SY, Sofocleous CT, Solomon SB, Gönen M, Peter Kingham T, Allen PJ, DeMatteo RP, Jarnagin WR, Hudis CA, D'Angelica MI. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. *Ann Surg*. 2016 Jul;264(1):147-54. doi: 10.1097/SLA.0000000000001371. PubMed [citation] PMID: 26445472, PMCID: PMC4818209
440. Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gönen M, Carlson D, Ganly I, Shah JP, Ghossein R, Patel SG. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. *Head Neck*. 2016 Apr;38 Suppl 1:E1192-9. doi: 10.1002/hed.24190. Epub 2015 Oct 30. PubMed [citation] PMID: 26514096, PMCID: PMC4996672
441. Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, **Gönen M**, D'Angelica MI, DeMatteo RP, Kingham TP, Groot Koerkamp B, Untch BR, Brennan MF, Jarnagin WR, Allen PJ. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. *Ann Surg Oncol*. 2016 Apr;23(4):1361-70. doi: 10.1245/s10434-015-4986-1. Epub 2015 Nov 23. PubMed [citation] PMID: 26597365, PMCID: PMC4798427
442. Grkovski M, Schwartz J, Gönen M, Schöder H, Lee NY, Carlin SD, Zanzonico PB, Humm JL, Nehmeh SA. Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. *J Nucl Med*. 2016 Mar;57(3):334-41. doi: 10.2967/jnumed.115.160168. Epub 2015 Nov 25. PubMed [citation] PMID: 26609178, PMCID: PMC4977990
443. Konstantinidis IT, Mastrodomenico P, Sofocleous CT, Brown KT, Getrajdman GI, Gönen M, Allen PJ, Kingham TP, DeMatteo RP, Fong Y, Jarnagin WR, D'Angelica MI. Symptomatic Perihepatic Fluid Collections After Hepatic Resection in the Modern Era. *J Gastrointest Surg*. 2016 Apr;20(4):748-56. doi: 10.1007/s11605-015-3041-7. Epub 2015 Dec 7. PubMed [citation] PMID: 26643300, PMCID: PMC4830382
444. Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, **Gönen M**, Levine RL, Nimer SD. Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. *J Exp Med*. 2016 Jan 11;213(1):25-34. doi: 10.1084/jem.20150524. Epub 2015 Dec 14. PubMed [citation] PMID: 26666262, PMCID: PMC4710200

445. Pugalenthi A, Protic M, **Gönen M**, Kingham TP, Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. *J Surg Oncol*. 2016 Feb;113(2):188-93. doi: 10.1002/jso.24125. Epub 2015 Dec 18. PubMed [citation] PMID: 26678349, PMCID: PMC4830358
446. Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. *Cancer*. 2016 Mar 1;122(5):758-65. doi: 10.1002/cncr.29824. Epub 2015 Dec 22. PubMed [citation] PMID: 26695839, PMCID: PMC4764409
447. Balachandran VP, Arora A, Gönen M, Ito H, Turcotte S, Shia J, Viale A, Snoeren N, van Hooff SR, Rinkes IH, Adam R, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. *Clin Cancer Res*. 2016 May 15;22(10):2575-82. doi: 10.1158/1078-0432.CCR-15-1071. Epub 2016 Jan 5. PubMed [citation] PMID: 26733613, PMCID: PMC4978939
448. Devlin SM, Ostrovnaya I, Gönen M. Boomerang: A method for recursive reclassification. *Biometrics*. 2016 Sep;72(3):995-1002. doi: 10.1111/biom.12469. Epub 2016 Jan 11. PubMed [citation] PMID: 26754051, PMCID: PMC4940305
449. Leung U, Gönen M, Allen PJ, Kingham TP, DeMatteo RP, Jarnagin WR, D'Angelica MI. Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. *Ann Surg*. 2016 Jan 13. [Epub ahead of print] PubMed [citation] PMID: 26764871, PMCID: PMC4942404
450. Eaton AA, **Gönen M**, Karanicolas P, Jarnagin WR, D'Angelica MI, DeMatteo R, Kingham TP, Allen PJ. Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. *Ann Surg Oncol*. 2016 Jul;23(7):2137-45. doi: 10.1245/s10434-015-5077-z. Epub 2016 Jan 19. PubMed [citation] PMID: 26786091, PMCID: PMC4891251
451. Brown KT, Do RK, **Gönen M**, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. *J Clin Oncol*. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1. PubMed [citation] PMID: 26834067, PMCID: PMC4966514
452. Kossatz S, Brand C, Gutiontov S, Liu JT, Lee NY, Gönen M, Weber WA, Reiner T. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. *Sci Rep*. 2016 Feb 22;6:21371. doi: 10.1038/srep21371. PubMed [citation] PMID: 26900125, PMCID: PMC4761964

453. Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, Morris L, Vaisman F, Corbo R, Momesso D, Vaisman M, Carvalho A, Learoyd D, Leslie WD, Nason RW, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, et al. An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. *Thyroid*. 2016 Mar;26(3):373-80. doi: 10.1089/thy.2015.0315. Epub 2016 Feb 25. PubMed [citation] PMID: 26914539, PMCID: PMC4790212
454. Oxnard GR, Wilcox KH, **Gönen M**, Polotsky M, Hirsch BR, Schwartz LH. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. *JAMA Oncol*. 2016 Jun 1;2(6):772-9. doi: 10.1001/jamaoncol.2015.6315. PubMed [citation] PMID: 26914340
455. Kingham TP, Leung U, Kuk D, Gönen M, D'Angelica MI, Allen PJ, DeMatteo RP, Laudone VP, Jarnagin WR, Fong Y. Robotic Liver Resection: A Case-Matched Comparison. *World J Surg*. 2016 Jun;40(6):1422-8. doi: 10.1007/s00268-016-3446-9. PubMed [citation] PMID: 26913732, PMCID: PMC4870111
456. Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. *J Nucl Med*. 2016 Sep;57(9):1350-6. doi: 10.2967/jnumed.115.170456. Epub 2016 Mar 3. PubMed [citation] PMID: 26940766
457. Hötker AM, Tarlinton L, Mazaheri Y, Woo KM, Gönen M, Saltz LB, Goodman KA, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. *Eur Radiol*. 2016 Mar 5. [Epub ahead of print] PubMed [citation] PMID: 26945761
458. Good MJ, Hurley P, Woo KM, Szczepanek C, Stewart T, Robert N, Lyss A, Gönen M, Lilenbaum R. Assessing Clinical Trial-Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool. *J Oncol Pract*. 2016 May;12(5):e536-47. doi: 10.1200/JOP.2015.008920. Epub 2016 Mar 22. PubMed [citation] PMID: 27006354
459. King TA, Lyman JP, **Gönen M**, Voci A, De Brot M, Boafu C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, MeszoelyIM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA. Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. *J Clin Oncol*. 2016 Jul 10;34(20):2359-65. doi: 10.1200/JCO.2015.63.1960. Epub 2016 Mar 21. PubMed [citation] PMID: 27001590, PMCID: PMC4981976
460. Sotirchos VS, Petrovic LM, **Gönen M**, Klimstra DS, Do RK, Petre EN, Garcia AR, Barlas A, Erinjeri JP, Brown KT, Covey AM, Alago W, Brody LA, DeMatteo RP, Kemeny NE, Solomon SB, Manova-Todorova KO, Sofocleous CT. Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. *Radiology*. 2016 Sep;280(3):949-59. doi: 10.1148/radiol.2016151005. PubMed PMID: 27010254; PubMed Central PMCID: PMC5006720.

461. Silberhumer GR, Paty PB, Denton B, Guillem J, **Gönen M**, Araujo RL, Nash GM, Temple LK, Allen PJ, DeMatteo RP, Weiser MR, Wong WD, Jarnagin WR, D'Angelica MI, Fong Y. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. *Surgery*. 2016 Jul;160(1):67-73. doi: 10.1016/j.surg.2016.02.029. Epub 2016 Apr 11. PubMed [citation] PMID: 27079362, PMCID: PMC4911703
462. Leal JN, Bressan AK, Vachharajani N, **Gönen M**, Kingham TP, D'Angelica MI, Allen PJ, DeMatteo RP, Doyle MB, Bathe OF, Greig PD, Wei A, Chapman WC, Dixon E, Jarnagin WR. Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation. *J Am Coll Surg*. 2016 May;222(5):766-79. doi: 10.1016/j.jamcollsurg.2016.01.046. Epub 2016 Jan 30. PubMed [citation] PMID: 27113514, PMCID: PMC4847545
463. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. *Eur J Nucl Med Mol Imaging*. 2016 Oct;43(11):1937-44. doi: 10.1007/s00259-016-3402-9. Epub 2016 Apr 30. PubMed [citation] PMID: 27129866
464. Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, **Gönen M**, Ziv E, Boas FE, Sofocleous CT. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. *Eur J Radiol*. 2016 Jun;85(6):1224-31. doi: 10.1016/j.ejrad.2016.03.029. Epub 2016 Mar 31. PubMed [citation] PMID: 27161074
465. Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, **Gönen M**, Jochelson M, Weber WA. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. *Am J Nucl Med Mol Imaging*. 2016;6(2):120-7. PubMed [citation] PMID: 27186439, PMCID: PMC4858608
466. van Klaveren D, **Gönen M**, Steyerberg EW, Vergouwe Y. A new concordance measure for risk prediction models in external validation settings. *Stat Med*. 2016 Oct 15;35(23):4136-52. doi: 10.1002/sim.6997. Epub 2016 Jun 1. PubMed [citation] PMID: 27251001
467. Doussot A, **Gönen M**, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, Allen PJ, Farges O, Kingham TP, Regimbeau JM, D'Angelica MI, Azoulay D, Jarnagin WR. Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. *J Am Coll Surg*. 2016 Sep;223(3):493-505.e2. doi: 10.1016/j.jamcollsurg.2016.05.019. Epub 2016 Jun 11. PubMed [citation] PMID: 27296525, PMCID: PMC5003652
468. Kelly KJ, Wong J, Gönen M, Allen P, Brennan M, Coit D, Fong Y. Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. *EBioMedicine*. 2016 May;7:94-9. doi: 10.1016/j.ebiom.2016.03.043. Epub 2016 Apr 2. PubMed [citation] PMID: 27322463, PMCID: PMC4909379
469. Grant F, Brennan MF, Allen PJ, DeMatteo RP, Kingham TP, D'Angelica M, Fischer ME, **Gönen M**, Zhang H, Jarnagin WR. Prospective Randomized Controlled Trial of Liberal Vs Restricted Perioperative Fluid Management in Patients Undergoing Pancreatectomy. *Ann Surg*. 2016 Jun 28. [Epub ahead of print] PubMed [citation] PMID: 27355261

470. Shady W, Sotirchos VS, Do RK, Pandit-Taskar N, Carrasquillo JA, **Gönen M**, Sofocleous CT. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. *AJR Am J Roentgenol*. 2016 Sep;207(3):661-70. doi: 10.2214/AJR.15.15202. Epub 2016 Jul 6. PubMed [citation] PMID: 27384594
471. Ma LW, Dominguez-Rosado I, Gennarelli RL, Bach PB, **Gönen M**, D'Angelica MI, DeMatteo RP, Kingham TP, Brennan MF, Jarnagin WR, Allen PJ. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial. *Ann Surg*. 2016 Jul 15. [Epub ahead of print] PubMed [citation] PMID: 27429029
472. Gollub MJ, Tong T, Weiser M, Zheng J, **Gönen M**, Zakian KL. Limited accuracy of DCE-MRI in identification of pathological complete responders after chemoradiotherapy treatment for rectal cancer. *Eur Radiol*. 2016 Jul 20. [Epub ahead of print] PubMed [citation] PMID: 27436029
473. Henssen AG, Jiang E, Zhuang J, Pinello L, Socci ND, Koche R, **Gönen M**, Villasante CM, Armstrong SA, Bauer DE, Weng Z, Kentsis A. Forward genetic screen of human transposase genomic rearrangements. *BMC Genomics*. 2016 Aug 4;17:548. doi: 10.1186/s12864-016-2877-x. PubMed [citation] PMID: 27491780, PMCID: PMC4973553
474. Devlin SM, Ostrovnaya I, **Gönen M**. Boomerang: A method for recursive reclassification. *Biometrics*. 2016 Sep;72(3):995-1002. doi: 10.1111/biom.12469
475. Cunanan KM, Iasonos A, Shen R, Begg CB, **Gönen M**. An Efficient Basket Trial Design. *Stat Med*. 2017 (in press).
476. Heller G, Seshan VE, Moskowicz CS, **Gönen M**. Inference for the difference in the area under the ROC curve derived from nested binary regression models. *Biostatistics*. 2016 Sep 21 (00): 1–15. doi:10.1093/biostatistics/kxw045.
477. van Klaveren D, **Gönen M**, Steyerberg EW, Vergouwe Y. A new concordance measure for risk prediction models in external validation settings. *Stat Med*. 2016 Oct 15;35(23):4136-52. doi: 10.1002/sim.6997.
478. Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I, Conrad M, Turker MZ, Gao M, Jiang X, Monette S, Pauliah M, **Gönen M**, Zanzonico P, Quinn T, Wiesner U, Bradbury MS, Overholtzer M. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. *Nat Nanotechnol*. 2016 Nov;11(11):977-985. doi: 10.1038/nnano.2016.164. PubMed PMID: 27668796; PubMed Central PMCID: PMC5108575.
479. Ulaner GA, Goldman D, Corben A, Lyashchenko S, **Gönen M**, Lewis J, Dickler M. A prospective clinical trial of 18F-Fluciclovine PET/CT neoadjuvant therapy response in invasive ductal and invasive lobular breast cancers. *J Nucl Med*. 2016 Nov 17. pii: jnumed.116.183335. [Epub ahead of print] PubMed PMID: 27856630.
480. Weber JS, Levit LA, Adamson PC, Bruinooge SS, Burris HA 3rd, Carducci MA, Dicker AP, **Gönen M**, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM. Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. *J Clin Oncol*. 2016 Nov 28;JCO2016704692. [Epub ahead of print] PubMed PMID: 27893329.

481. Cunanan KM, **Gönen M**, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. *J Clin Oncol*. 2016 Nov 28;JCO2016699751. [Epub ahead of print] PubMed PMID: 27893325.
482. Leal JN, Sadot E, **Gönen M**, Lichtman S, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. Operative morbidity and survival following hepatectomy for colorectal liver metastasis in octogenarians: a contemporary case matched series. *HPB (Oxford)*. 2016 Nov 30. pii: S1365-182X(16)31902-5. doi: 10.1016/j.hpb.2016.09.009. [Epub ahead of print] PubMed PMID: 27914765.
483. Hötker AM, Tarlinton L, Mazaheri Y, Woo KM, **Gönen M**, Saltz LB, Goodman KA, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. *Eur Radiol*. 2016 Dec;26(12):4303-4312. PubMed PMID: 26945761.
484. Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, **Gönen M**, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. *Nat Med*. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. PubMed PMID: 27841873.
485. Zheng J, Kuk D, **Gönen M**, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, Jarnagin WR, DeMatteo RP. Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. *Ann Surg Oncol*. 2016 Dec 5. [Epub ahead of print] PubMed PMID: 27921192.
486. Shia J, Schultz N, Kuk D, Vakiani E, Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR, Wolchok JD, Boland CR, **Gönen M**, Klimstra DS. Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. *Mod Pathol*. 2016 Dec 16. doi: 10.1038/modpathol.2016.198. [Epub ahead of print] PubMed PMID: 27982025.

Book

1. **Gönen M**. Receiver Operating Characteristic Curves Using SAS®. SAS Press, Cary, NC. 2007.

Book Chapters

1. Kattan MW, **Gönen M**, Scardino PT. The development and execution of medical prediction models. In *Outcome Prediction in Cancer*. Edited by Taktak AFG, Fisher AC. Elsevier. 2007.
2. **Gönen M**. Bayesian Analysis. In Kattan MW (editor) *Encyclopedia of Medical Decision Making*. Sage, 2009.
3. **Gönen M**. Bayesian t-test and Beyond. In Bang, H, Zhou, XK, Van Epps, H, Mazumdar, M. (editors) *Statistical Methods in Molecular Biology*. Humana Press, Springer, 2010.